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Abstract
Tyrosine kinases (TKs) are a family of signalling proteins of great pharmaceutical im-
portance, as they are involved in the regulation of most cellular pathways. TKs catalytic
activity is strictly regulated by conformational changes and post-translational modifi-
cations, and their deregulation is involved in numerous human diseases, ranging from
cancer to autoimmune diseases. Among tyrosine kinases, Abl and Src are of particular
interest for cancer research. The Abl domain in the BCR-Abl fusion protein is the main
cause of chronic myeloid leukemia, and it was the target of the first successful anti-
leukemic therapy, the powerful kinase inhibitor imatinib. We now know that imatinib
effectively inhibits BCR-Abl, as well as Kit and Lck kinases, by binding to a specific
inactive state, in which the conserved Asp-Phe-Gly motif (DFG) assumes a peculiar
"out" conformation. Still, there are many questions on its mode of action. For instance,
other TKs with an extended identity with Abl (such as Src, which has 45% sequence
identity) bind much less strongly to imatinib, in spite of very similar binding mode.
Moreover, the mode of action of drug-resistant mutations that induce imatinib resis-
tance and cause an increasing number of relapses in patients under treatment, is still
poorly understood. Understanding the molecular mechanisms responsible for the ob-
served differences in imatinib activity, is essential for the development of new selective
anticancer drugs. In this thesis, by using computational and experimental approaches,
I have investigated the reasons leading to drug resistance and the differential binding
affinity in homologous TKs. A combination of enhanced sampling molecular dynam-
ics simulations (such as parallel tempering metadynamics or PTmetaD) were used to
reconstruct and compare the free energy landscape associated with the relevant con-
formational changes. Mutagenesis and isothermal titration calorimetry were used to
validate the computational results.
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Preface
Protein kinases (PKs) are a large family of signalling proteins that regulate a plethora
of cellular functions by phosphorylating protein and non-protein substrates. They cur-
rently are the most important anti-cancer targets, and we now count more than 100
kinase inhibitors in clinical use or in an advanced development phase [1]. Thanks to
the recent technological advancements in drug discovery, including those in computer-
aided drug design, more powerful inhibitors have been developed, but the search for
selective and effective PKs inhibitors is far from over. This is due, on the one hand,
to the complex interplay between conformational changes, protein allostery and drug
binding mechanisms. On the other, to the emergence of drug resistance, which makes
the most advanced inhibitors and therapies ineffective. To overcome these problems, a
deeper comprehension of the regulatory mechanisms in PKs is needed.
In this Ph.D. project, I have studied in great detail the role of the conformational
dynamics and cancer-causing mutations in the regulation and de-regulation of selected
members of the tyrosine kinase (TK), family of PKs. The TKs studied were chosen
for their great historical and biomedical importance. In the first chapter, I summarise
the recent literature on the subject. In the second chapter, I describe the computational
methods employed and the experimental techniques used to validate the computational
results. In the third, fourth and fifth chapters, I discuss the molecular mechanisms
responsible for the observed differences in the imatinib activity and in the sixth the
mode of action of several drug-resistant mutations. The seventh and last chapter is
devoted to final considerations and conclusions.
Chapter 1
Introduction
TKs are very dynamic structures (plastic, flexible), and both their activity and regu-
lation are influenced by coupled movements on different timescales[2, 3]. While fast
and localised atomic vibrations are involved in the catalytic activity of TKs, slower
conformational changes are crucial to regulation.
In this respect, only recently the role of sub-µs dynamics in proteins has been
recognised as crucial in the regulation of conformational changes, binding of ligands
and allostery. In this section, I will give a general overview of how the view of proteins
as dynamical entities has changed and evolved over the years.
1.1 The modern view of dynamics and allostery in
proteins
1.1.1 Dynamics of proteins: the link between structure and
function
The view of proteins as dynamic entities has evolved with time. Initially thought as
static in the "lock and key" model of enzyme activity[4], they were soon recognised as
flexible entities in the "induced fit" theory by Koshland in 1963[5]. Finally in the early
80s, experimental evidence for the dynamics of enzymes both in presence and absence
of substrates[6, 7, 8], founded the concept of proteins as flexible systems. For the first
time, dynamics was seen as an essential requirement for enzyme activity, and the link
between structure and biological function in proteins.
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The dynamics of proteins is strictly correlated to the amino acid sequence, with
backbone atoms in helices and strands being more restrained than those in loops. Nowa-
days proteins are seen as in constant fluctuation among different conformations[9, 10].
In particular, conformations adopted by proteins during catalysis seem to be already
pre-sampled in the free enzyme, suggesting that the crucial motions for catalysis are
intrinsic property of enzymes, deeply encoded in their sequence[11]. Therefore, the
biological function is strictly associated with protein dynamics, and the biological pro-
cesses are mainly determined by alterations in the populations rates of catalytically
competent conformations, rather than by on/off mechanisms[3].
Computationally, energy landscapes could be effectively used to describe the con-
formational space of proteins. Thus the relative probability of every conformation can
be defined as well as the energy barrier between one conformation and another. Since
protein dynamics is defined by both the timescale and the amplitude of the protein
motions, the energy landscapes of proteins turn out to be highly multidimensional[2].
1.1.2 The hierarchy of dynamics in proteins: motions on different
timescales
To get a comprehensive description of the energy landscape of proteins, a method that
samples their dynamics over a wide range of timescales is required (see Figure 1.1).
Kinetically different conformations are usually separated by high energy barriers, thus
the interchange among them happen at slow timescales (µs, ms or slower). In Figure
1.1 it can be seen that these slow conformational changes belong to what is defined by
Frauenfelder et al. as ’tier-0’[2]. The transitions of tier-0 are usually associated to large
and rare conformational changes, involved in lots of biological processes. However,
within the energy minimum (tier-0), proteins are not static but experience ps to ns
fluctuations (tier-1 and tier-2 dynamics)[2]. Proteins can sample a large amount of
closely related conformations, separated by low energy barriers. If tier-0 is mostly
characterised by large domain motions, tier-1 and tier-2 define fast motions, such as
movements of loops and rotation of side-chains.
From experiments (e.g. NMR), it has become clear how close is the connec-
tion between fast and slow dynamics, since the first is the physical origin of the
latter[12, 13, 14, 15]. Changes in the fast dynamics (sub-µs dynamics), closely de-
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Figure 1.1: Free energy profile following the different timescales and amplitude of motions
in proteins, as in the classification made by Frauenfelder et al.[2, 3]. Slow conformational
changes happen at higher free energy values (rare events), at slower timescale (tier-0) and they
are characterised by motions of bigger amplitude. Faster motions could be found in tier-1 (ns
timescale) and in tier-2 (fs), mostly associated with bonds vibration and side-chains rotation.
Figure taken from Ref [2].
pendent by the amino acid sequence, have an influence on the more complex domain
motions of proteins[16]. This hierarchy in the dynamics of proteins, both in time and
space (timescale and amplitude of motions), is certainly encoded in the amino acid
sequence, but it is also strictly connected to protein allostery[17].
1.1.3 The integrated view of protein allostery
Proteins are able to react to external stimuli via long-range communication, and this
communication is essential for every biological event. They interact with tens of sub-
strates, ligands and other proteins at specific sites within their structure. The effect of
these interactions is then propagated to regions far away in structure, letting the signal
flow. This potent regulatory process, referred as allostery, is also responsible for cru-
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cial conformational changes in proteins. A ligand, for example, could provoke changes
involved in the ultimate regulation of a biological process, such as the adoption of a
functionally active conformation[18].
In the allosteric theory of Monod-Wyman-Changeux in 1965[19], the protein is
seen in equilibrium between two major conformations, and the ligand may perturb this
equilibrium, binding to one conformation and provoking a conformational change that
will stabilise the other (see Figure 1.2, image b). The current view of protein allostery
add complexity to this theory, taking into consideration protein dynamics[9]. Today
proteins are seen as plastic structures, fluctuating among different conformations. The
binding of a ligand determines the reshape of their free energy landscapes, binding to a
pre-existing conformation and inducing a shift in the population rates[10] (see Figure
1.2, image a and c).
Figure 1.2: Representations of the reshaping that the energy landscapes of proteins could expe-
rience after ligand binding. In black is the energy profile before ligand binding, in red the new
profile upon ligand binding. (a) The ligand selects for a conformation among many equally
stable conformations. (b) The ligand binds to a stable native conformation of a protein de-
termining a conformational change that leads to another stable conformation. (c) The ligand
binds to a stable native conformation bringing to a more heterogeneous landscape of accessible
conformations. Figure taken from Ref [10].
1.2 Tyrosine kinases as paradigms of highly dynamic
structures
Tyrosine kinases (TKs) are very dynamic structures, perfect example of proteins with a
highly multidimensional landscape, characterised by the adoption of several conforma-
tions, even if just a few are of relevance to this study. Indeed, the work presented in this
thesis is focused on the study of the conformational dynamics associated with the "ac-
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tive to inactive" conformational switch in the kinase domain (KD) of TKs. Hereafter,
I will describe more in detail the KD structure, and in particular the structural features
involved in the conformational changes and the allosteric network of the kinase.
1.2.1 Structure and conformational changes in tyrosine kinases
The kinase KD consists of about 250 residues and comprises a smaller N-terminal lobe
and a larger, helix reach, C-terminal lobe (see Figure 1.3). At the interface between the
lobes, lies the ATP (adenosine triphosphate) binding site formed by a number of highly
conserved residues.
Tyrosine kinases have been observed in a variety of different conformations, active
and inactive. Activation leads to ATP binding and is mainly controlled by conforma-
tional changes in three conserved structural motifs: the DFG-motif, the activation loop
(A-loop) and the αC-helix[20](see Figure 1.3).
Figure 1.3: Front view of the Abl kinase domain (a) with highlighted in different colours the
most important structural features and in sticks the tyrosine residue of the activation loop (in
green), which phosphorylation activates the kinase. (b) Side view of Abl with a more detailed
view of the DFG motif (in orange sticks) and of its two possible conformations, DFG-in and
DFG-out.
The A-loop is a highly flexible region connecting the two lobes and can assume
an ensemble of different conformations, going from a fully open to a closed form (see
Figure 1.4), which hides the binding site (also called active site). When the A-loop
is in an extended fully-open conformation, a specific tyrosine can be phosphorylated
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Figure 1.4: Schematic representation of the possible conformations a tyrosine kinase can as-
sume. There is just one active conformation, with well defined structural characteristics to fulfil
(DFG-in, A-loop open, αC-helix Glu-in) but many inactive intermediate conformations, with
different arrangements the catalytic important elements can adopt. Among them just one is of
interest in the context of this thesis work, and is the inactive DFG-out conformation in which
the drug imatinib (in magenta sticks) binds to the kinase active site (A-loop closed, αC-helix
Glu-in).
leading to kinase activation(see Figure 1.3, image a). On the contrary, all other possible
A-loop conformations are considered inactive. The Asp-Phe-Gly (DFG) motif, at the
N-terminus of the A-loop, is able to flip from an ’in’ to an ’out’ form (Figure 1.3 and
Figure 1.4). In the active conformation, the Asp is pointing towards the ATP binding
site (DFG-in or Asp-in) and the Phe away from it, occupying an hydrophobic pocket,
while in the inactive conformation Asp and Phe exchange their positions (DFG-out or
Asp-out). The DFG-in to DFG-out flip has been proposed to have a functional role
in the release of the product of catalysis (adenosine diphosphate, ADP). Finally, the
so-called αC-helix, localised in the N-lobe (Figure 1.3), has a glutamate that, both
in the active and inactive conformations (Figure 1.4), is forming a salt-bridge with a
lysine in the active site (αC-in or Glu-in). In the passage from active to inactive, the
kinase adopts an intermediate conformation in which the glutamate of the αC-helix
interrupts the salt-bridge with the lysine to form a new one, with an arginine of the
A-loop, adopting a Glu-out position (see Figure 1.4).
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1.2.2 Allostery in tyrosine kinases
The process by which a subtle perturbation in a region of a protein could be amplified
and determine the motion of tens of residues, is still debated. TKs are the paradigm
of signalling proteins and their activity is finely tuned by allostery. Even if the struc-
tural elements involved in the kinase allosteric network (see Figure 1.5) have been
identified[17], their interplay is not completely understood. Moreover, the allosteric
mechanisms within every kinase are unique and associated with protein conformational
changes[21].
Figure 1.5: Regions of the kinase domain involved in the allosteric network of TKs. The
different colours identify every element of the network: P-loop in pink, αC-helix in cyan, DFG
motif in orange, A-loop in green and the αG-helix in wheat. Imatinib is shown in red sticks
binding to the kinase active site.
Figure 1.5 reports the structural elements part of the allosteric network in most
TKs, involved in the conformational changes of the kinase domain, mentioned in the
previous section, and essential for ATP and drug binding. Some areas of the structure,
shown in Figure 1.5, such as the αC-helix, the DFG motif, the A-loop are directly
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involved in the conformational changes of the kinase domain, but others such as the P-
loop and the αG-helix, experience a repositioning as a result of allosteric modulation.
Important for the structural integrity of the kinase core and also because consid-
ered part of the allosteric network[17] are: the catalytic spine (C-spine) and the reg-
ulatory spine (R-spine) (see Figure 1.6). These "spines" are two hydrophobic motifs,
conserved among all kinases, and postulated to play a role in guaranteeing the kinase
with an efficient and robust catalysis[22, 23, 24]. Described for the first time in the
PKA kinase, both the C-spine and the R-spine span from the N-lobe to the C-lobe, cre-
ating a stable net of hydrophobic interactions, enabling the right positioning of the ATP
and the substrate during the transfer of the phosphate group. The spines are fully as-
sembled in the active kinase, while they are disrupted when the kinase is inactive. The
C-spine (see Figure 1.6, in yellow) is completed by the adenine ring when ATP is bound
to the binding site while, the R-spine is the first to be assembled as a consequence of
A-loop phosphorylation (see Figure 1.6, in red). Moreover, the R-spine comprises cat-
alytic important elements, such as the Phe of the DFG motif and a residue (Leu) of the
αC-helix.
Figure 1.6: Protein Kinase A (PKA) structure where hydrophobic spines have been detected
for the first time. View of kinase domain with the catalytic spine (C-spine) shown in yellow and
the regulatory spine (R-spine) shown in red. Figure taken from Ref [23].
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1.3 Tyrosine kinases and their deregulation in cancer
TKs were chosen as subjects of this study because of their great historical and biomed-
ical importance as anti-cancer drugs targets[25]. In this section, I give first a general
overview of the TK family, followed by a more detailed description of the TKs consid-
ered in the study.
1.3.1 The tyrosine kinase family
TKs are a large and diverse family of enzymes whose central role is to catalyse the
transfer of a γ-phosphate from the ATP molecule to the amino acid acceptor on protein
substrates[26] (see Figure 1.7). The phosphorylation event is crucial in the regulation
Figure 1.7: Catalytic cycle of a tyrosine kinase protein. Figure taken from Ref [26].
of cellular signalling and numerous biochemical reactions, under normal and patholog-
ical conditions[27]. Their deregulation is related to several human diseases, including
diabetes, inflammation, cardiovascular diseases and cancer. The role of TKs in the reg-
ulation of cell cycle, cell proliferation and apoptosis makes them the most important
targets for anti-cancer treatments[28, 29].
TKs are further divided into two families: the non-receptor tyrosine kinases, lo-
calised in the cytoplasm, and the receptor tyrosine kinases (RTKs), on the cell mem-
brane. RTKs are constituted by three domains: an extracellular, a transmembrane and
an intracellular catalytic domain. The binding of a ligand to the extracellular domain is
often coupled to oligomerisation, causing conformational changes in the structure re-
sulting in enzyme activation. The active enzyme is able to fulfil its biological function,
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and thus to bind and phosphorylate cytoplasmic substrates[30]. The phosphorylation of
intracellular proteins triggers a cascade of events for the transduction of the signal di-
rectly to the nucleus, where gene expression is regulated. In a similar way, non-receptor
tyrosine kinases regulate several cellular functions by phosphorylating enzymes in re-
sponse to events happening in the cytoplasm.
In pathological conditions, as in cancer, TKs become constitutively active, deter-
mining an uncontrolled phosphorylation of the kinase substrate, often leading to cell
proliferation[31, 32].
Hereafter, it follows a brief description of the TKs considered in the study, to elu-
cidate their cellular function and the result of their pathological deregulation. Src and
Abl kinases were the main focus of this work because both targets of the successful
anti-cancer drug imatinib (introduced later). Lck, Kit, Met and EGFR were later in-
cluded in the work, and chosen for their high sequence homology (more than 45%) to
both Src and Abl, and because imatinib targets.
1.3.2 The Src tyrosine kinase
Src is the homologue of the first discovered retroviral oncogene, v-Src. This gene,
found in the Rous Sarcoma virus (RSV) is responsible for provoking uncontrolled mi-
tosis of host cells, inducing sarcoma[33]. The enzyme is constituted by three domains:
Figure 1.8: Structure of Src kinase. The full-length kinase is constituted by three domains:
SH2, SH3 and kinase domain (KD, the only considered in this study). The different spatial
orientation of the domains discriminates between the inactive and active forms, adoptable by
Src. For the activation or inactivation of the full-length kinase, crucial are two sites of phospho-
rylation: Tyr527 of the C-terminal tail (phosphorylated in the inactive form) and Tyr416 of the
activation loop (phosphorylated in the active form). Figure taken from Ref [34].
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the SH2 and SH3 domains, localised at the N-terminus of the structure and connected,
by a linker, to a larger catalytic domain (or kinase domain, KD), where the ATP binding
site is present[35, 36, 37](see Figure 1.8).
The catalytically active form of Src, activated by the phosphorylation of Tyr416 on
the activation loop (A-loop), is responsible for cell movement and proliferation. In the
auto-inhibited conformation the phosphorylated Tyr527, localised on the C-terminal
tail, interacts with the SH2 domain, while the linker with the SH3 leading to a closed
conformation [34, 38, 39]. In cancer, Src is found in a constitutively active form, lack-
ing the inhibitory phosphorylation site (Tyr527).
1.3.3 The Abl tyrosine kinase
Abl is a cytoplasmic tyrosine kinase encoded by the ABL1 gene placed on the chromo-
some 9. When a reciprocal translocation, between chromosome 9 and 22 occurs, the
BCR-Abl fusion gene is formed. The union of the ABL1 gene (originally on ch9) with
the BCR gene (on ch22) generates the so called "Philadelphia chromosome”, most
commonly associated with chronic myeloid leukemia (CML)[40].
a b
Figure 1.9: Cartoon representation of the Abl structure. (a) The full-length kinase is constituted
by three domains: SH2, SH3 and kinase domain (KD, the only considered in the study). The
kinase is in the inactive form with the myristate tail (Myr) docked to the hydrophobic pocket in
the C-lobe. (b) Cartoon representation of the activated form of Abl, with the peculiar position
adopted by the SH2 domain, on top of the kinase domain. Figure taken from Ref [41].
Abl is homologous to Src and the modular arrangement of SH2, SH3 and catalytic
domain is common to both tyrosine kinases. The KD is connected at the N-terminus
with the SH2 subunit by a linker, at which follows the SH3 (see Figure 1.9, image a).
When activated by phosphorylation of the tyrosine on the activation loop (A-loop), the
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kinase undergoes a large conformational change in which the SH2 domain moves at the
top of the KD (see Figure 1.9, image b). Only inferences can be made about the position
adopted by the SH3 in this process, since no crystal structures are available[42]. The
protein encoded by the fusion gene (BCR-Abl) preserves Abl, with the exception of the
myristate tail (Myr in Figure 1.9), a small N-terminal region before the SH3 subunit.
The myristate tail docks to a hydrophobic pocket in the C-lobe of the protein, keeping
it in an inactive form[43] (see Figure 1.9, image b). The loss of the myristate tail
determines the deregulation of Abl kinase, resulting in the insurgence of CML.
1.3.4 Other tyrosine kinases of interest
Activating mutations of the genes codifying for TKs are associated with different types
of cancer. For instance, Kit, in its mutant deregulated form, is responsible for the
insurgence of gastrointestinal stromal tumours (GST)[44], EGFR of lung cancers[45],
while Lck and Met are mostly involved in the metastatic process[46, 47].
Lck, the lymphocyte-specific protein, is found in specialised cells of the immune
system, the T-cells. In normal conditions, it phosphorylates the tyrosine residue of the
cluster of differentiation 3 (CD3) and of the T-cell receptor complex in the cell cyto-
plasm. After the phosphorylation event, a signalling cascade is started and it culminates
with the intracellular release of Ca2+ ions, crucial for the activation of many signalling
processes within the cell. Among them, the production of cytokines that promote lym-
phocytes proliferation[47].
The enzymes Kit, Met and EGFR are all tyrosine kinase receptors (RTKs). Kit
is expressed on the surface of hematopoietic stem cells. When the ligand, the stem
cell factor, binds to the protein it dimerises becoming active. The phosphorylation
of second messengers in the cell determines the propagation of the signal, regulating
proliferation and cell growth[44]. The Met kinase, also called hepatocyte growth factor
receptor because of its ligand, the hepatocyte growth factor, is expressed on membranes
of epithelial cells. When activated by the ligand, is involved in many important signal
transduction pathways, such as the RAS pathway, the PI3K pathway and the STAT
pathway among others. In normal conditions Met is responsible for mitogenesis and
morphogenesis[46, 48]. Finally, the epidermal growth factor receptor (EGFR) is known
to bind diverse growth factors. When a ligand binds, the formation of homodimers
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or heterodimers is promoted and the signal transduction pathway initiated. EGFR is
normally responsible for DNA synthesis and cell proliferation[49, 45, 50].
1.4 Tyrosine kinases as anti-cancer drugs targets
TKs have been the most attractive anti-cancer targets of the last decade[1, 51, 52]. Most
TKs inhibitors are small ligands binding to the ATP binding site. One of biggest suc-
cess of drug discovery[52], leading to a revolution in the treatment of chronic myeloid
leukemia (CML) first, and gastrointestinal stromal tumours (GST) later, was the dis-
covery of imatinib, commercialised with the name of Gleevec.
However, the different inhibitor activity (IC50) of imatinib towards highly homol-
ogous TKs led to a major effort in the scientific community for the identification of the
underlined mechanisms responsible for the observed differences.
Therefore in this section, after a brief overview of imatinib discovery and its use in
therapy, I describe the several efforts and hypothesis formulated over the past 10 years,
in the attempt to explain imatinib diverse activity towards TKs and its mechanism of
binding.
1.4.1 Chromic myeloid leukemia and imatinib "promiscuity"
In 2001 the effective kinase inhibitor imatinib[53] was approved for the treatment of
CML[54, 55]. Ninetyfive percent of patients, suffering for CML, are chromosome
Philadelphia positive (Ph+) (see Section 1.3.3) and express the BCR-Abl fusion protein.
CML is responsible for an uncontrolled myeloid cell proliferation in the bone marrow,
with a subsequent abnormal accumulation of white cells in the blood[54, 55, 40].
Imatinib was developed to specifically target BCR-Abl[53, 56, 57]. The clinical
success is due in particular to its stunning efficacy in the early stages of CML, where
ninety percent of patients respond to the treatment, showing a complete remission [58,
59]. In stark contrast, 60% of patients, treated in an advanced stage of the disease,
relapse in the long term due to the onset of drug-resistance [60].
Imatinib turned out to be not so selective[61] and to target, besides Abl, many other
TKs (see Table 1.1). Imatinib inhibits effectively BCR-Abl[62], binding competitively
to the ATP binding site of the kinase, but it is also successfully used in the treatment of
gastrointestinal stromal tumors (GST), because of its serendipidous affinity for Kit[63].
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TK IC50 (µM)
Abl 0.037 [62]
Kit 0.3 [63]
Lck 9 [56]
Met >100 [64, 65]
EGFR >100 [66]
Src >100 [66, 65]
Table 1.1: IC50 values of imatinib activity towards each of the targeted TKs. Lower IC50 values
corresponds to a better imatinib activity (better kinase inhibition).
Although imatinib binds also to other kinases, such as Src, Met and EGFR among
others, it does not effectively inhibit any of them[66, 60], despite the high sequence
homology and x-ray structures showing the same binding mode to the active site[20]
(see Figure 1.10). All the mentioned TKs have a 45% sequence homology with the
KD of Abl, or even more if considering only the binding site, that is nearly identical.
Puzzling is the case of Lck, quite effectively inhibited by imatinib[56][60], despite the
high sequence identity with the KD of Src (70%).
Figure 1.10: Binding mode of imatinib to Src and Abl obtained by x-ray crystallography. In
sticks is shown the DFG motif adopting the "out" conformation. Imatinib adopts the same
binding pose in both kinases. Figure taken from Ref [20].
Imatinib binds to the inactive (DFG-out) conformation of Src (see previous Sec-
tion 1.2.1) with a 3000 times lower affinity than to Abl, resulting in a 4.6 kcal/mol
penalty in binding energy[20]. This mismatch between drug affinity and structural
similarity has been addressed numerous times in the past years but its molecular causes
are still debated.
Initially, it was proposed that this difference was due to the inability of TKs, other
than Abl, to adopt the DFG-out conformation[62, 67]. This hypothesis has soon been
discarded, because of crystal structures showing imatinib-bound conformations of Src,
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Kit and Lck[20, 68, 69]. In the light of these findings, it was proposed that the DFG-out
conformation might play an important functional role and be accessible to many, if not
most, kinases[70]. Subsequently, Seeliger et al.[20] ascribed the low imatinib activity
towards Src to a difference in the conformation adopted by the P-loop region of Abl,
which seems to rearrange upon drug binding (see Figure 1.11). This loop has been
crystallised adopting a kinked conformation in the Abl-imatinib complex, while in Src
and Kit it remains unchanged[20]. Since Kit is effectively inhibited by imatinib despite
not showing a kinked P-loop, also this hypothesis was discarded.
Figure 1.11: X-ray structure of Abl in the DFG-out conformation with imatinib bound. At a
side, detailed image of the P-loop region. To be noted is the kinked conformation adopted by
the P-loop (in red) and ascribed to reorientation of residue Tyr253 (in sticks). In Src and Kit
instead of a tyrosine there is a phenylalanine. Coloured in green the αC-helix and in yellow the
A-loop. Imatinib is shown in grey sticks. Figure taken from Ref [20].
At some point, also the protonation of residue Asp404, of the DFG motif, was hy-
pothesised to influence the DFG-out stability, and therefore the binding of imatinib to
Abl[70]. The DFG-out population in Abl was seen to increase around pH=6 and subse-
quently drop at pH'7 (see Figure 1.12). Similarly, the Kon of imatinib binding to Abl
drops around pH=7.5 (see Figure 1.12). Thus, at physiological conditions (cytoplasmic
pH=7.2) the DFG-out population, able to bind imatinib, will be minimal.
Seeliger and co-workers also performed an extensive mutagenesis study[20], sub-
stituting residues of the binding site of Src into the corresponding ones of Abl, but they
did not manage to show any substantial increase in the imatinib affinity for Src. More-
over, crystal structures and free energy calculations have shown that imatinib binds
to the same residues, engaging in the same interactions in the binding sites of Src and
Abl[71]. It follows that an answer should be looked for not in the structure of these pro-
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Figure 1.12: (A) pH dependence of imatinib binding to Abl wild-type (in black). (B) Variation
of the percentage of the DFG-out population of Abl corresponding to different pH values (in
black). (C) Binding rates of imatinib to Abl WT at different pH show high pH dependence
for the binding. (D) Binding rates of dasatinib to Abl WT at different pH show weak pH
dependence (dasatinib binds to the DFG-in conformation). Figure taken from Ref [70].
teins, but in the dynamics, kinetics and thermodynamics of the conformational changes
they undergo.
1.4.2 Binding of Imatinib: conformational selection or induced
fit?
The scaffold of imatinib is formed by a 2-phenylaminopyrimidine (see Figure 1.13
rings C and D), substituted with a benzamide-piperazine (rings A and B) and a pyridine
(ring E). As shown in crystal structures of Src and Abl in complex with imatinib[20],
the drug binds to the inactive (DFG-out) conformation of the kinase, adopting a bridge
position above the DFG motif (see Figure 1.14), occupying both the ATP site, with
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rings E and D, and the hydrophobic pocket (also called allosteric pocket) with rings A
and B (see Figure 1.14). In Figure 1.13, the interactions imatinib makes, common to
Abl, Src and the other TKs can be seen. Of particular interest are the ones it makes
with the "gatekeepers" (Thr315 and Met319), Asp381 and Glu286, because they are all
found to be mutated in patients showing drug resistance (see following Section 1.5.1).
AB
CD
E
Figure 1.13: Structure of the drug imatinib. In dotted lines are shown the interactions it makes
when bound to the kinase. The residues are common to Src and Abl. Figure taken from Ref
[72].
The binding of imatinib to TKs seems to be influenced by different factors, primar-
ily by the conformation of the DFG motif and the A-loop. The A-loop gains importance
because when closed it is limiting the access to the binding site. Moreover, at the N-
terminal region of the A-loop, there is the DFG motif which flip, from ’in’ to ’out’, it
is known to be crucial for the binding to happen.
Figure 1.14: Imatinib binding to the active site of the kinase occupying both the ATP pocket
and the allosteric pocket. When imatinib is bound, the kinase is adopting the DFG-out, inactive,
conformation. Coloured in green is the DFG motif, in yellow the A-loop.
When the kinase is active (DFG-in), the A-loop is phosphorylated and it adopts an
open conformation (see Section 1.2.1). It has been shown, in a recent work by Roux
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et al.[73] on the Src KD, that when the A-loop is not phosphorylated, it can exists in a
multi-state equilibrium of active and partially active conformations (see Figure 1.15).
On the contrary, the phosphorylation locks the kinase in a catalytically active conforma-
tion (see Figure 1.15). Thus, phosphorylation stabilises the open conformation of the
A-loop and the DFG-in as well, determining a shift in populations towards the active
conformation, not targeted by imatinb[62].
Figure 1.15: Free-energy surfaces of Src KD with A-loop not phosphorylated (a) and phospho-
rylated (b). The not phosphorylated surface (a) shows more energy minima while, the phospho-
rylated form (b) only one, corresponding to the open A-loop conformation. The method used in
the study is the Umbrella Sampling enhanced method[74]. On the x-axis, the distance describ-
ing the A-loop closed (lower values) to open (higher values). On the y-axis, the subtraction of
two distances describing the switch of the αC-helix from the Glu-in (higher values) to Glu-out
(lower values) conformation. Figure taken from Ref [73].
Experiments performed on the phosphorylated and not phosphorylated forms of
Abl, Src and Kit (see Figure 1.16), showed that the imatinib affinity for Src remains
almost unaltered by the phosphorylation event[75] while, it is almost 30-fold reduced
towards phosphorylated Abl[76, 20] and Kit[77]. This huge change in affinity towards
both imatinib sensitive kinases, could be explained by considering that the druggable
DFG-out conformation of Abl and Kit would be much more populated in the non-
phosphorylated form of the two kinases, with respect of what would be for Src. Thus,
the population shift towards the active conformation for Abl and Kit, due to phospho-
rylation, would result in a more drastic effect on the imatinib activity.
Also striking is the finding that phosphorylation seems to impair the binding only
of imatinib and not of other anti-cancer drugs, such as dasatinib[76] and sunitinib[77].
The main difference between these drugs is the conformation of the kinase they tar-
get, for which we already know a major discriminant is the A-loop conformation. As
discussed previously, imatinib binds to the inactive conformation (DFG-out, A-loop
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closed) while, both dasatinib and sunitinib bind to the active conformation (DFG-in,
A-loop open). Since the difference in activity of imatinib for TKs seems not to be so
Figure 1.16: Response curves of drugs binding to the phosphorylated (p) and not phospho-
rylated (np) forms of Src (a) Abl (b) and Kit (c). Drug affinity has been tested with different
methods in the three studies thus, values could not be directly compared. (a) Fraction bound of
imatinib to Src "pY412" and "npY412". (b) Response curves of imatinib and dasatinib binding
to Abl "p" and "np". It was also tested a mutant of Abl, in which phosphorylation has been
impaired by mutating the tyrosine of the A-loop (Y393F). (c) Response curves of imatinib and
sunitinib binding to Kit. The label "activated KIT" stands for phosphorylated while, "inactivate
KIT" for not phosphorylated. Figure (a) taken from Ref [75], Figure (b) taken from Ref [76]
and Figure (c) taken from Ref [77].
strongly influenced by individual structural features or sequence (see Section 1.4.1),
more could be ascribed at the overall stability of TKs conformations, with a particular
focus on the DFG motif and A-loop conformations.
The binding mechanism of imatinib to TKs has been long discussed, and both a
conformational selection and an induced fit mechanism have been proposed[20, 78, 15,
79, 80].
In the works of Kern et al.[79, 80] it was proposed, on the basis of NMR and
kinetics studies, that the higher affinity of imatinib for Abl might be due to an induced
fit binding mechanism, related to the rearrangement of the P-loop region (kinked P-
loop, discussed in Section 1.4.1 and shown in Figure 1.11). This rearrangement is
supposed to happen after the docking of imatinib to the binding site. However, not to
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forget is the crucial role played in first instance by the sampling, in both Src and Abl,
of the druggable DFG-out conformation for the binding to take place, also underlined
in other studies[78, 81].
In general, the hypothesis that both mechanisms could play a role in the binding
of ligands to their targets has been postulated. It seems that the binding process could
be described as a combination of two steps. A first step dominated by conformational
selection mechanism, happening on larger time-scales, complemented by a second step
of induced fit, more localised at the binding site[82, 83].
Moreover, a common statement in many of the works performed on Src and Abl,
points to the fact that it is difficult to find a unique explanation for the different imatinib
affinity, and that the free-energy penalty of binding could arise "from a distributed set
of factors"[20].
1.5 Drug-resistance in tyrosine kinases
After the discovery of imatinib[53], a considerable effort has been devoted to the design
and registration of new active, kinase targeting, anti-cancer drugs[84]. The demand for
second-line drugs became even more urgent with the appearance of imatinib resistant
cellular strains[85]. Indeed, the treatment with imatinib selects those cells harbouring
mutations[86]. Still today, drug resistance remains the main drive for the development
of new Abl inhibitors, because it is responsible for the relapses and the poor diagnosis
of many chronic myeloid leukemia patients[65].
In this section, I describe the most common mechanisms of resistance and the
advances in the molecular understanding of this phenomenon, together with the new
drugs and strategies available to overcome imatinib resistance.
1.5.1 Imatinib and resistance
The numerous resistant mutations observed can be classified according to the degree
of resistance they confer to the kinase inhibitor[87]. Mutations that can be overcome
by increasing the dose of the drug are generally considered as conferring a lower de-
gree of resistance, while those conferring a high degree of resistance are considered
irreversible [65, 58].
Most imatinib resistant mutations are localised in the KD of Abl [88, 89] (see Fig-
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ure 1.17) and some of them are directly involved in the binding. A classical mechanism,
by which these missense mutations lower the affinity of the kinase for the inhibitor, is by
abrogating specific molecular interactions, crucial for the stability of the binding[90]
(see Figure 1.17). One of the most lethal mutations in Abl is the T315I, called the
”gatekeeper’ mutant[91] (see Figure 1.17), where the substitution of a threonine with
an isoleucine eliminates an hydrogen bond crucial for the high-affinity binding of the
drug.
Many other mutations (F317L, L387M, V379I, Y253F/H and F359V, see Figure
1.17), all lying in the active site, have a similar mechanism of action: they destabilise
the binding or simply prevent it by steric hindrance[92]. Unfortunately, for several other
resistance-causing KD mutations the mechanism of action is still unknown, because
some of them are localised far from the active site or because are not directly involved
in the destabilisation of the binding[88] (see Figure 1.17).
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Figure 1.17: Abl KD (a) with resistant mutations highlighted (b). Green dots are those mutants
with a known mechanism of action (e.g. elision of crucial bonds for the stability of the binding),
while the red dots are the ones whose mechanism is still unknown[93].
Experimentally, it is known that the level of resistance to imatinib depends not
only on the type of amino acid substitution[95], but also on the site where the mutation
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Figure 1.18: (a) Survival curves of patients expressing non P-loop and P-loop mutations. (b)
Abl second messenger STAT5 phosphorylation levels for Abl WT and resistant mutants of Abl
(T315I, G250E, G250A). T315I ("gatekeeper" mutant) and G250E (P-loop mutant) are not
inhibited at high imatinb doses (above 5 µM, high degree of resistance). Figure (a) taken from
Ref [94] and Figure (b) taken from Ref [95].
arises. As an example, patients expressing imatinib resistant mutations in the P-loop
region (G250E/A, Q252H, Y253F, E255V/K), have on average worse survival rates[94]
(see Figure 1.18). In particular, the study of Mahon et al.[95] shows very well how the
substitution glycine to glutammate (G250E) is much more potent (higher phosphoryla-
tion rates of the substrate STAT5[96] of BCR-Abl) than that of the glycine to alanine
(G250A, see Figure 1.18, image b). It seems clear though that even a single amino acid
change could be critical for drug activity[97].
In the light of these findings and of the previously described binding mode of
imatinib (adopting a bridge position over the DFG motif when in DFG-out, see Section
1.4.2), the interplay among sequence, site of the mutation and conformational dynamics
should not be underestimated.
Imatinib resistance has clear mutational hotspots within the TK structure[98].
Mapping them could be useful in ranking the importance played by every region of
the structure, and its relation with the binding and the affinity of the drug. Bioinformat-
ics studies have revealed that many oncogenic mutations occur in conserved positions
along the KD[98] and that these hotspots are recurrent and shared by several TKs[99].
The conservation of structure and often of sequence of mutations, suggests a conserved
mechanism of drug resistance among kinases[1].
Recent computational studies, on oncogenic Abl, EGFR, B-Raf and FGFR[100,
101, 102, 103] kinases, have shown that, most of the times, mutations have an impact
that goes beyond the mutated site, leading to wider allosteric changes in TKs (see Fig-
ure 1.19). They could determine a mutation-induced modulation responsible for confor-
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mational selection and population shifts[100, 98, 101]. For example, mutations could
be responsible for "cracking points" in proteins, enhancing partial unfolding events.
The "cracking" theory ascribes to local unfolding to act as a catalyser of transitions in
proteins, making possible global conformational changes[104, 105, 106].
Figure 1.19: Free-energy surfaces of EGFR WT and of three EGFR oncogenic mutants
(L858R, T790M and T790M-L858R). The mutations are responsible for a shift in the con-
formational space sampled by the kinase, leading to the stabilisation of the active conformation
(open active-like A-loop and αC-helix Glu-in). Figure taken from Ref [100]
All major kinase inhibitors used in therapy educe drug resistance responses[107,
108, 109, 90]. A plausible mechanism for the mode of action of these resistant mutants,
would be the destabilisation of the protein conformation with a high affinity for the
drug (e.g. inactive, DFG-out conformation, in the case of imatinib) or the stabilisation
of low affinity ones[89, 110, 111] (e.g. kinase active conformation, see Section 1.4.2).
Detecting the features responsible for the selectivity and the resistance to imatinib could
provide crucial information for the rational design of more effective and less toxic
anticancer drugs.
1.5.2 Alternative strategies and drugs to overcome resistance
While in their catalytically competent (active) conformation TKs share a common fold,
inactive conformations are numerous and highly diverse. The high structural homol-
ogy among kinases complicates the search for selective inhibitors. Targeting inactive
conformations is one of the strategies used to achieve a restricted selectivity[28].
Four classes of kinase inhibitors are successfully used in therapy, the main differ-
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ence being their binding mode[112, 51]. Imatinib is known as a type II drug. Type II
drugs bind to the inactive (DFG-out) conformation of the kinase, occupying both the
ATP site and the adjacent allosteric pocket, that is freed due to the rearrangement of
the A-loop and the peculiar Asp-out position adopted by the DFG motif[113] (see Fig-
ure 1.20). Due to the insurgence of imatinib resistance, alternative inhibition strategies
have been developed along the years[1, 109, 114, 90]. Variability in the scaffolds or in
the mode of binding of drugs have been used to overcome resistance. This is the case of
nilotinib and sorafenib, type II drugs as imatinib but with slightly modified structures.
On the contrary, dasatinib, sunitinib and lapatinib are type I drugs, that bind to the ac-
tive (DFG-in) conformation of the kinase, occupying only the ATP site, right below the
P-loop region[115, 108] (see Figure 1.20).
A-loop
A-loop
P-loop
Figure 1.20: Binding modes of the two major classes of kinase inhibitors, Type I and Type II.
Type I drugs bind to the ATP pocket, below the P-loop region, type II drugs occupy both the
ATP and the allosteric pockets, adopting a bridge position over the DFG motif at the N-terminal
of the A-loop.
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More recently, allosteric kinase inhibitors have been introduced in therapy, used
alone or in association with active site binders[85]. These drugs bind to remote sites of
the structure, causing conformational changes responsible for the kinase inactivation.
In the case of Abl, particularly exploited is the myristate pocket, located in the C-lobe
(see Section 1.3.3). Drugs such as GNF-2 and GNF-5 are the most renown myristate
binders[85, 15]. Their use in association with imatinib, has been successful in many
cases of resistance, including the "gatekeeper" mutant T315I[85, 109].
Finally, there are the covalent inhibitors, that bind irreversibly to the ATP site.
They could be either peptides, analogues of the biological substrate of the kinase, or
small molecules specifically designed to target a cysteine residue present in the active
site of most kinases[116, 117].
In the search for efficient TKs inhibitors, pivotal would be the understanding of
the complex interplay among sub-µs dynamics, conformational changes and allostery
in these targets.
Chapter 2
Materials and Methods
In this thesis I have used a combination of enhanced sampling atomistic molecular
dynamics (MD) simulations and biophysical experiments to characterise the confor-
mational dynamics and the flexible binding of ligands to a set of oncogenic tyrosine
kinases.
Notwithstanding a large increase in the available computer power and much faster
MD codes, most ligand binding and conformational changes events are still out of reach
of atomistic simulations. This is due to the limited time-scales that can be simulated
with atomistic MD that, even on the largest supercomputers[118], range from hundreds
of ns to a few µs.
Since the aim of this thesis was the study of events (such as large-scale confor-
mational changes in tyrosine kinases, TKs) that happen on longer time scales (ms),
the use of enhanced sampling algorithms was required. The algorithm of choice was
parallel tempering metadynamics (PTmetaD)[119], found to be very effective in sam-
pling large scale conformational changes in TKs, and allows an accurate free energy
reconstruction. I also used advanced analysis techniques to analyse the allosteric net-
work connecting remote sites to the binding pocket. The expression and purification
of the proteins to perform the biophysical experiments also required a lengthy trial and
error procedure to optimise the yield. These are described below together with ITC
approaches.
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2.1 Computational Methods
2.1.1 Molecular Dynamics
Molecular dynamics (MD) simulations were used to compute the equilibrium proper-
ties of classical many-body systems, whereby a collection of N mutually interacting
particles obey the laws of classical mechanics[120]. The time evolution of a system
of N atoms, with Cartesian coordinates r i, can be simulated by integrating Newton’s
equation of motion over time:
F i(r1, ...,rN) = mir¨ i (2.1)
where mi is the mass of atom i, r¨ i the acceleration of atom i and F i = −∇r iV is the
force acting on each atom, and V the potential (from the molecular mechanic force
field). In practice, the previous set of coupled equations are solved numerically using
the velocity-Verlet integrator[121, 122, 123]. Every time step, forces are calculated
and new atoms positions updated in a trajectory file[120]. To assure the conservation
of energy and the long term stability of the simulation, the time step needs to be ('
10 times) faster than the fastest vibrations (bond stretching), typically limiting the time
step in the range of 1-2 fs.
The force field describes the potential energy of the system under analysis[124,
125, 126]. The most used force fields in classical MD simulations are still mainly
based on the formulation by Lifson[127] originally devised in the 60s. This functional
form is the result of two main contributions, the bonded and non-bonded interactions,
defined as follows:
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where Kr, Kθ and Kn are force constants, req and θeq are the equilibrium bond length
and bond angle respectively. φ is the dihedral angle with δ being the phase angle. εi j is
the Lennard-Jones well depth and r0i j is the distance at which the value of the Lennard-
Jones potential is zero, while the minimum is located at 21/6r0i j. qi and q j are the partial
atomic charges, ri j the distance between them and ε0 is the dielectric constant.
This simple functional form of the force-field neglects important contributions,
such as the polarizability, but still it provides a good compromise between speed
and accuracy. The most recent non-polarizable protein force-fields such as Amber
ff99SB*ILDN[128, 129] and CHARMM22*[130, 131] are remarkably accurate, thanks
to a significant re-parametrization effort, based on the comparison of the simulations
to high-level ab-initio calculations and NMR experiments[132]. These force-fields are
accessible through widely used molecular dynamics packages such as: AMBER[133],
GROMACS[134], ACEMD[135], CHARMM[136], NAMD[137] and Desmond[138].
Most of these codes are parallel and can take advantage of graphics processing units
(GPUs).
Still, computing the non-bonded interactions (electrostatic and van der Waals), for
systems containing 50,000 or more particles, is time consuming. Even using a cut-
off or more advanced approaches to reduce the computational cost of computing the
electrostatic potential, such as the Particle Mesh Ewald (PME) method[139].
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Integrating the equations of motion more than a billion times (equivalent to 2 µs, if
the time step is set to 2 fs) to sample conformational changes, is prohibitively expensive
even on a large-scale super-computer. Thus the need for enhanced-sampling algorithms
to address this "timescale” problem is evident.
MD simulations are usually performed within the canonical (NVT) or isothermal-
isobaric (NPT) ensembles, that maintain a constant number of particles (N), tempera-
ture (T), volume (V) or pressure (P), respectively[120]. In the NVT ensemble the sys-
tem exchanges energy with a thermostat. Several are available, the more popular are:
the Berendsen thermostat[140], the Nosé-Hoover thermostat[141], the velocity-rescale
thermostat[142] and the Langevin thermostat[120]. While, the most commonly used
barostats are: the Berendsen barostat[140] and the Parrinello-Rahman barostat[143].
Due to its robustness, fast equilibration times and simple implementation the
velocity-rescale thermostat was used in the work presented in this thesis, while the
Parrinello-Rahman algorithm was used to equilibrate the system pressure. Moreover,
also the Langevin thermostat and the Berendsen barostat were used in simulations per-
formed with the ACEMD software.
2.1.2 Enhanced sampling algorithms and free energy calculations
The "timescale” problem is currently one of the main limitations of MD simulations.
For this reason many algorithms to enhance the sampling and reconstruct free ener-
gies have been proposed. Broadly speaking, these algorithms can be classified in four
categories[144, 145, 146]:
• Methods to enhance the sampling as a function of one or a few predefined
collective variables (CVs) (e.g. Umbrella Sampling[147, 74], Thermodynamic
Integration[148], Metadynamics[149, 150, 151] and its derivatives such as Par-
allel Tempering Metadynamics[119], Multiple Walkers Metadynamics[152],
Bias Exchange Metadynamics[153], Path Collective Variables[154], Steered
MD[155], Reconnaissance Metadynamics[156].).
• Methods in which the phase space is explored simultaneously at different
values of the temperature (e.g. Parallel Tempering[157], Parallel Tempering
Metadynamics[119]).
2.1. Computational Methods 55
• Methods aimed at exploring the transition mechanism and constructing reac-
tive trajectories (e.g. Path Collective Variables[154], Steered MD[155], String
method[158, 159], Thermodynamic Integration[148]).
• Methods for exploring the potential energy surface and localising the saddle
points that correspond to the transition states (e.g. Metadynamics[149, 150, 151],
Multiple Walkers Metadynamics[152], Transition Path Sampling[160], Markov
State Models[161]).
Extensively applied in this thesis, for the reconstruction of the DFG flip conformational
change (DFG-in to DFG-out), was the Parallel Tempering Metadynamics method[119]
combining a CV-based method to Parallel Tempering.
2.1.3 Metadynamics and Parallel-Tempering Metadynamics
One of the most effective and widely-used family of enhanced-sampling algorithms
is Metadynamics (metaD)[149, 150]. Metadynamics allows for a fast and accurate
exploration of the free energy surface (FES). The FES is the reconstruction of the sys-
tem free-energy as a function of collective variables (CVs). Thus, metaD is somewhat
similar to CV-based approaches such as Umbrella Sampling[147, 74]. It requires the
identification of a set of CVs that are able to describe the process of interest (e.g. con-
formational change, binding of ligand or a chemical reaction). It can treat several CVs
(usually up to 4) simultaneously, and can be used both for reconstructing the free energy
and for accelerating rare events.
The dynamics in the space of the chosen CVs is enhanced by a history-dependent
potential constructed as a sum of Gaussians (or rational functions) centred along the
trajectory followed by the CVs. The CVs need to describe the reaction coordinate
and include all the slow degrees of freedom relevant to the reaction. When all the
free energy basins for the system have been explored, the free energy surface can be
reconstructed by integrating the bias.
It has been recently proved that the well-tempered implementation of Metadynam-
ics provides an unbiased estimate of the free energy of the system projected onto prede-
fined CVs[162]. However, the convergence time depends critically on how optimal are
the CVs. Diverse and highly versatile CVs have been implemented over the years in
the open source PLUMED plug-in package, increasing the success of the method[163].
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The Vbias(s) is added at defined time-intervals (τG) as Gaussians, with a given
height (w) and width (σ ), chosen by the user. The main aim of metaD is the filling of
energy basins with ’tailored’ Gaussians (w and σ ), enabling the system to overcome
high energy barriers and to explore a wider conformational space (see Figure 2.1).
Figure 2.1: Gaussians are added along the CV space to help the system overcoming energy
barriers during the metaD simulation (a). When the entire conformational space is filled with
Gaussians (b), the added bias is summed (c) and the FE profile reconstructed (d). Figure taken
from Ref [164].
In the well-tempered metaD[151], the height w of the Gaussians is rescaled over
time. w tends to zero with the increase of the simulation time, as ∝ 1t , leading to a fast
convergence and a correct free energy reconstruction:
w = ωe−
V (s,t)
∆T τG (2.3)
where ω is the initial deposition rate of the Gaussians and τG is the time interval for
the deposition. Over time, the variation of the bias potential will be so small, that the
system will be considered at equilibrium, and converged to the right free energy value:
V (s, t→ ∞) =− ∆T
∆T +T
F(s) (2.4)
where ∆T∆T+T is the bias factor. ∆T could be tailored by the user in order to accelerate
the crossing of energy barriers and the exploration along the s space.
2.1. Computational Methods 57
Well-tempered metaD solved many of the convergence problems of standard
metaD. Still the main limitation remains the strong dependence on the choice of the
CVs. Indeed, forgetting a relevant "slow” variable could lead to extremely slowly con-
verging free energy reconstructions, making the approach impractical.
The Parallel Tempering Metadynamics method (PTmetaD)[119], used in this
study, was developed to minimise the convergence problems due to the choice of the
CVs. PTmetaD is a combination of well-tempered[151] Metadynamics (metaD)[149,
150] and Parallel Tempering (PT)[157] methods. The combination of the two (PT+
well-tempered metaD) permits to overcome the weaknesses of both methods, and to
enhance effectively the sampling of conformational landscapes, to compute fully con-
verged free energy.
PT helps accelerating MD simulations, running replicas of the same system at
different temperatures[157], resembling the Replica Exchange Molecular Dynamics
(REMD) method[165]. The replicas of the system running at higher temperatures man-
age to cross FE barriers more easily than it would do at lower temperatures thus, explor-
ing a wider conformational space. Every MD simulation runs in parallel at a specified
temperature (T1<T2<...<TN), for a total of N replicas. Periodically, an exchange be-
tween the coordinates of two neighbour replicas (T1 and T2) is attempted (see Figure
2.2), and accepted with a probability:
P(acc) = min1
{
exp[(
1
kBT2
− 1
kBT1
)(U2−U1)]
}
(2.5)
where kB is the Boltzmann constant for the two replicas of the system, T is the tem-
perature and U is the potential energy. The acceptance for the exchange follows the
Metropolis criterion and depends on the potential energy of the two conformations
(U1 = U2). The coupling of systems at different temperatures assures the enhanced
sampling along all degrees of freedom. However, to improve the sampling of specific
conformational changes of interest, PT is associated with well-tempered metaD.
The PTmetaD free energy surface (FES) is finally obtained by reconstructing the
FE of the system at a specific temperature T . However, in the summation of the added
Gaussians, a ∆T (bias factor) increase has to be considered, to account for the altered
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Figure 2.2: Schematic example of the exchanges happening among replicas at different tem-
peratures during a Parallel Tempering simulation. Figure taken from Ref [166].
probability distribution in the s space. The choice by the user of w (height of the
Gaussians), σ (width of the Gaussians) and τG (time interval for the deposition of
Gaussians) is decisive for the accuracy of the sampling, and of the FE reconstruction.
As mentioned before, critical for the set up of the metaD calculation, is the choice
of CVs that best describe the process to investigate. Even if with metaD is possible
to treat several CVs simultaneously, limiting the number of variables is preferable, in
order to prevent poor computational performances. In the light of this, the use of PT
in combination with metaD, provides for the neglected CVs, thank to the enhanced
sampling assured at higher temperatures.
2.1.4 Classical MD simulations details
In this thesis, classical MD simulations of several tyrosine kinases (TKs) were per-
formed, considering the kinase catalytic domain (KD). The KD counts 260 amino acids.
Crystal structures of the KD, adopting the DFG-in conformation, were retrieved from
the Protein Data Bank, PDB entries Src:2SRC, Abl:2G1T, Kit:1PKG, Lck:3KMM,
Met:2WGJ and EGFR:2ITW.
Missing residues were added with the Modeller software[167], according to the
respective Uniprot sequences. The Amber99SB*-ILDN[128, 168, 169] force field was
employed and the topology files were created with AMBER[133], using TIP3P[170]
water molecules in a cubic box, with periodic boundary conditions and a minimum dis-
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tance of 10 nm between the protein and the boundaries. The system charges were neu-
tralised, adding the proper number of positive (Na+) or negative (Cl-) ions. The systems
of all TKs were minimised with 10000 steps of conjugated gradient and equilibrated
using ACEMD[135] in the NPT ensemble for 10 ns, using a Berendsen barostat[140]
at 1 atm. The temperature was kept at 310K by a Langevin thermostat[120]. Classical
MD simulation were carried out for all the systems in the NVT ensemble with a time
step of 4 fs. The runs of Abl, Src and Kit were extended to a total length of 1 µs, for
testing purposes, while runs of Lck, Met and EGFR were 400 ns long. All MD simu-
lations were performed with the ACEMD program[135] running on a server with four
Nvidia Fermi GPUs. The van der Waals interactions were cut off at 1.0 nm, and the
long range electrostatic interactions were calculated by the PME algorithm[139] with a
mesh spaced 0.1 nm.
The same MD setup was employed in the simulations of the resistant mutants
of Abl (G250E, E279K, H396P, E450K and T315I) and of the engineered mu-
tants of Src (Q275A/P299Q/Q420E, Q275G/P299E/Q420A, Q275A/P299Q/V461S,
Q275A/P299Q/Q309A, E415G/Y416G/V461S, E415G/Y416G, M302G and αC
chimera). The mutations were modelled in-silico using the Modeller software[167].
All MD simulations of the mutants last for 400 ns.
2.1.5 Trajectory analysis
Root mean square deviation analysis
The root mean square deviation analysis (RMSD) was used to monitor the behaviour of
the structure during the MD simulation. The displacement of the system with respect to
the initial, equilibrated, structure gives an insight of the stability and changes undergone
by the system. The analysis was performed using the g_rms tool of GROMACS[134]
and considering the atoms of the backbone.
Root mean square fluctuation analysis
To study sub-µs dynamics in TKs, root mean square fluctuation analysis (RMSF) was
performed using the tool g_rmsf of the GROMACS[134] package. The fluctuations of
every Cα atom, with respect to a reference structure, were averaged along the trajec-
tory. The first 50 ns of the MD trajectory were discarded, based on the RMSD analysis,
because considered equilibration time. To remove the effect of large scale conforma-
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tional changes, the analysis was calculated on overlapping windows of 100 ns each and
averaged, taking as reference the initial structure after equilibration time.
Principal component analysis
To investigate the essential dynamics and the dominant motions in TKs, principal com-
ponent analysis (PCA)[171, 172] was performed using GROMACS[134]. The covari-
ance matrix of the MD trajectory was calculated with g_covar, considering the protein
backbone. The eigenvectors and eigenvalues, generated by the diagonalisation of the
covariance matrix were analysed with the tool g_anaeig. To consistently compare the
conformational space visited by every kinase with respect to Abl (chosen as reference
of a flexible kinase in the study), the trajectories of all TKs and resistant mutants of Abl
were projected on Abl first and second eigenvectors.
Solvent accessible surface area analysis
The solvent accessible surface area analysis (SAS)[173, 174] was used to compare the
dimension of the kinase binding site in the DFG-in and DFG-out conformation of Src
and Abl.
Short classical MD simulations (20 ns) were performed using as starting structures
the most representative DFG-in and DFG-out conformations, extracted from the free
energy minima of the PTmetaD calculations and then clustered using g_cluster tool.
The SAS analysis was performed using the GROMACS[134] tool g_sas, based
on the double cubic lattice method discussed in Ref [174]. The binding site cavity
of both kinases was defined by residues: 275-279, 296-340 and 391-412 (PDB 2SRC
numbering). Since the data point of the MD trajectory would not be independent,
the SAS analysis was calculated on 100 structures randomly chosen for both DFG-in
and DFG-out simulations. The process was repeated 100 times and the SAS averaged
afterwards. Default values were used for the number of dots per sphere (24) and the
water probe radius (0.14 nm).
Subsequently, the count of water molecules in the cavity for both DFG-in and
DFG-out conformations was performed using the VMD program[175]. As for the SAS
analysis, the calculation was repeated 100 times and the number of waters averaged
afterwards, determining the water molecules within 5 Å from the residues of the DFG
motif.
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pKa calculation
As discussed in the Introduction 1.4.1, it was proposed that the DFG flip transition
could be influenced by the protonation of residue Asp404 of the DFG motif. To address
this hypothesis, pKa of Asp404 was calculated for both Src and Abl on 10000 structures
with the program PROPKA[176, 177]. Subsequently, the values were averaged.
The structures were extracted from the short MD simulations (20 ns) per-
formed in the DFG-in and DFG-out conformations (see Section 2.1.5). The program
PROPKA[176, 177] calculates the pKa value of residue Asp404. It does so, by sum-
ming to the intrinsic pKa of the residue, retrieved by solving the linearised Poisson-
Boltzmann equation, the environmental perturbation acting on the residue. The fi-
nal pKa perturbation (∆pKa) is given by the sum of the hydrogen bonds contribution,
charge-charge interactions and desolvation effect depending on the protein burial.
Allosteric coupling analysis
Allosteric coupling analysis was performed in order to identify correlated motions
along normal modes in TKs. Normal modes is a fast method to reconstruct patterns of
motion in proteins, calculating vibrational modes and protein flexibility. The method of
Balabin et al. was applied[178]. It consists of a combination of normal modes analysis
and first order perturbation theory.
The normal modes of Src, Abl, Kit, Met and EGFR were retrieved using the
Anisotropic Network Model[178, 179], taking into consideration only the Cα atoms
of the minimised structure. Subsequently, a first order perturbation is applied to ev-
ery Cα atom, treated as a spring and displaced along the normal mode[180]. Then
the alignment between the displaced (Figure 2.3, coloured in magenta) and the starting
structures (see Figure 2.3, in blue) is performed to eliminate translational and rotational
motions. In this way, it is possible to identify just the structural perturbation and better
distinguish between correlated and non correlated regions. Finally, the RMSD between
the aligned (see Figure 2.3, in red) and the starting structures gives the local perturba-
tion for each Cα atom (see Figure 2.3), considering 10 Å cut-off for the neighbour list.
The net allosteric coupling is measured on the total displacement of every Cα atom
along all the normal modes.
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Figure 2.3: Graphical representation of the coarse-grained atom displacement as described in
the method of Balabin et al.[178]. Figure taken from Ref [178].
2.1.6 Enhanced sampling simulations details
Well-tempering PTmetaD
Well-tempered PTmetaD method[119, 151] was used in the work presented in this the-
sis to accelerate the sampling of large conformational changes and to reconstruct an
accurate and reliable free-energy for Src and Abl. The choice of the computational
expensive PTmetaD method is due to the complexity of the biological transition of
interest for this study, the DFG-flip (DFG-in to DFG-out).
Simulations of Src and Abl KD were performed using 28 well-tempered PTmetaD
replicas at different temperatures, ranging from 308K to 399K. The topology files
were prepared using AMBER[133], as described in Section 2.1.4, and converted using
Acpype[181] into GROMACS[134] input files. The systems were minimised with 1000
steps of steepest descent and subsequently equilibrated. A first equilibration step was
performed in the NPT ensemble for 10 ns, using a Parrinello-Rahman barostat[143],
followed by a second equilibration step of 10 ns canonical ensemble, at 300K with a
velocity-rescale thermostat (described by Bussi et al. in Ref[142]).
For the FE simulations, version 4.6 of the molecular dynamics program
GROMACS[134] was used, with the PLUMED plug-in (version 1.3)[163], running
on 280 Xeon Nehalem cores connected by an Infiniband network. The van der Waals
interactions were cut off at 1.1 nm, and the long-range electrostatic interactions calcu-
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lated by the PME algorithm[139] with a mesh spaced of 0.12 nm. The neighbour list
for the non-bonded interactions was updated every 0.02 ps. The systems were sampled
in the NVT ensemble, coupled with a velocity-rescale thermostat[142] and a time step
of 2 fs.
An exchange of coordinates between replicas at two adjacent temperatures is at-
tempted every 1 ps. The initial height of the Gaussians was 2 kJ/mol, the bias factor 5
and the deposition rate of 1/2000 steps. The width of the Gaussians, that determines the
resolution of the recovered free energy surface, was set to 0.03 nm for the distance CVs
(described below) and to 0.1 nm for the dihedral combination CV. Every well-tempered
PTmetaD run required almost 3 months of uninterrupted simulations on 280 processor
cores, for a total of 400 ns performed for each of the 28 replicas.
As mentioned previously (Section 2.1.3), in the PTmetaD method is necessary the
identification of a set of CVs able to describe the process of interest. In this thesis,
to identify the CVs that better describe and discriminate conformational change of the
DFG motif, crystal structures of Src and Abl were analysed, together with the trajecto-
ries of the MD simulations performed.
Four CVs able to give a geometrical description of the flip were identified. The
set used in the PTmetaD simulations of Src and Abl comprises three distances and one
dihedral combination, described as follows (see Figure 2.4):
• CV1 is the distance between residue <D404> of the DFG motif and residue
<K295> of the β3 strand (<> denotes the centre of mass of the residue). CV1
was aimed to describe the flip of D404 thus, as counterpart residue K295 having
a limited range of movements was chosen (see Figure 2.4).
• CV2 is the distance between residue <F405> of the DFG motif and L317(Cβ )
for Src/I293(Cβ ) for Abl, residues of the αC-helix (see Figure 2.4). Residues
L317 and I293 were chosen due to a peculiar movement of residue I293 of Abl,
detected analysing the MD trajectory.
• CV3 is a dihedral combination of residues D404, F405 and A408, f (φ404,ψ405,
ψ408) as shown in Figure 2.4. f is a continuous function ranging from 3, if the
three dihedral arguments correspond to the DFG-in position, to 0 if they are in
the DFG-out conformation.
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• CV4 is the distance between residues<N381,...,H384> and residues<A408,...,I411>
(see Figure 2.4). CV4 was aimed to describe the movement of the N-terminal
part of the A-loop, region immediately after the DFG motif.
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Figure 2.4: Collective variables chosen for the well-tempered PTmetaD simulations of Src
and Abl. 2SRC.pdb numbering considered, with the exception of the residue I293 in Abl that
corresponds to L317 in Src. In detail, the CV3 dihedral combination of the DFG motif. Figure
taken from Ref [93].
PTmetaD in well-tempered ensemble
The well-tempered PTmetaD method[119, 151] allows the accurate sampling of rare
events in biological systems. However, the high computational cost depending on the
number of replicas needed to simulate large systems (e.g. more than 35000 atoms) is
still a huge limitation. The main advantage in using the PTmetaD in a well-tempered
ensemble (WTE)[182, 183], is the possibility to obtain good performances (high ex-
changing rates among temperatures), reducing the number of replicas. In the WTE
ensemble, the average potential energy remains approximately the same of the canoni-
cal ensemble, but with enhanced fluctuations (see Figure 2.5). The enhancement of the
fluctuations is obtained by tuning the γ factor, to ensure a better overlap between the
potential energy of each replica:
V (U, t→ ∞) =−(1− γ−1)F(U) (2.6)
with γ=(T+∆T)/T ≥ 1 and F(U)=U-β−1 lnN(U)).
In practice, the first 20 ns of simulation were used to converge the bias in the
only potential energy space. Subsequently, PTmetaD-WTE simulations were continued
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considering the other CVs, adding the history-dependent metaD bias to the static bias,
previously generated. At the end of the simulation, both the bias and the trajectory
corresponding to the first 20 ns were discarded and the FES reconstructed as usual in
function of the CVs.
Figure 2.5: Comparison of the potential energy fluctuations for two replicas in a normal NVT
simulation and in a WTE simulation. Figure taken from Ref [184].
The simulations of the resistant mutants of Abl (G250E, E279K, H396P, E450K
and T315I) were performed using only 5 replicas (compared to the 28 of the well-
tempered PTmetaD), using temperatures at 300K, 318K, 337K, 356K and 399K. The
systems were simulated as described in Section 2.1.6 using the same set of CVs (see
Figure 2.4). The Gaussians added along the potential energy space had initial height 2
kJ/mol and width 140. The bias factor was 16 and the γ factor was 2.24 (square root of
the bias factor). The simulations converged after reaching 400 ns with the exception of
G250E and T315I, converged at 640 ns and 1200 ns, respectively. Overall, the sampling
time was of 15 µs across all mutants.
Metadynamics using path collective variables
The path collective variables (PCV)[154], implemented in PLUMED[163], were used
as CVs in the Metadynamics simulations to reconstruct the free energy of the drug
imatinib binding to Abl WT and the "gatekeeper" mutant (T315I). The starting structure
used was the crystal structure of Abl with imatinib bound (PDB code 1IEP). The mutant
T315I with imatinib bound was modelled in silico using Modeller[167].
The path collective variables[154] are meant to find low free energy pathways
along the system reaction coordinate. Two CVs, the s− path and the z− path, are used
2.1. Computational Methods 66
to describe the evolution of the system along a predefined path. The path is constituted
by a set of conformations (X) that represent all the relevant intermediates describing
the transition from XA to XB.
The s− path describes the progress of the system along the path and is defined as
follows:
s− path = ∑
N
i=1 iexp(−λd[X−Xi]2)
∑Ni=1 exp(−λd[X−Xi]2)
(2.7)
The z− path describes the distance of the system from the path:
z− path =− 1
λ
ln
[
N
∑
i=1
exp(−λd[X−Xi]2)
]
(2.8)
where N is the number of conformations Xi that constitute the path. At every time step
is calculated the RMSD distance of the system from the path, d[X−Xi]2.
For the path to be meaningful, the conformations should be chosen as equidistant
as possible, in a way that the system could follow the path without discontinuities. To
obtain a smooth path the term λ should be chosen as follows:
λ =
2.3(N−1)
∑N−1i=1 d[Xi−Xi+1]2
(2.9)
For this thesis, a suitable path describing the (un-)binding mechanism of imatinib to
Abl was extracted from a preliminary Metadynamics simulation, performed by Mr
Michael Hayne a previous student in the group. Sixteen conformations (considering
the only Cα atoms) were extracted from the lowest free-energy pathway of the metaD
simulation, and then used as CV (s− path). The z− path, distance from the path, was
set by defining an upper wall (UWALL=1) in the PLUMED input file. The walls are
constraints usually used to limit the CV space explored. The same path (s− path) was
used for the simulations of the T315I mutant.
2.1.7 Rational choice of PTmetaD parameters
As mentioned previously in Section 2.1.3, when performing a PTmetaD simulation
some parameters have to be chosen by the user, and this choice could determine the
outcome of the simulation. In particular, speed and accuracy may depend on the height
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(w), width (σ ) and deposition rate (τG) of the Gaussians. Hereafter, I briefly describe
the best way to choose these and other parameters, in order to assure a reliable sam-
pling. Figure 2.6 shows an example of the PLUMED[163] input file needed to perform
PTmetaD simulations.
If the height (HEIGHT in Figure 2.6) and width (SIGMA in Figure 2.6) of the
Gaussians (HILLS in Figure 2.6) are too high, the resolution of the free-energy recon-
struction will be compromised while, if they are too low the simulation will take very
long to fill the energy minima and to converge. Thus, as a rule of thumb:
• the W_STRIDE, in Figure 2.6, defines the deposition rate of the Gaussians and
how often (time steps) is written the HILLS output file. It is usually chosen to be
1 ps.
• the HEIGHT of the Gaussians should be usually around 1.5-2 kJ/mol. It could
be higher or lower, depending on the system and how deep is expected to be the
energy minimum.
• the SIGMA should correspond to half of the CV fluctuation at equilibrium (ex-
pressed in nm). This is usually determined on the basis of preliminary MD sim-
ulations.
• the BIASFACTOR (Figure 2.6) is chosen between 5 and 10, depending on the
expected height of the energy barrier to cross.
In the input file, the CVs to consider during the simulation are defined (CV DEF-
INITION in Figure 2.6) by specifying the atoms or groups of atoms constituting each
of the CV (GROUP DEFINITIONS in Figure 2.6). The values of the CVs along the
simulation are written in the COLVAR output file, with a frequency specified by the
command PRINT W_STRIDE (see Figure 2.6). Additional parameters are the upper
and lower walls (UWALL, LWALL in Figure 2.6), constraints used to limit the CV
space to explore. If the CV value becomes greater than the fixed wall limit (LIMIT
in Figure 2.6) then, a restraining potential starts acting on the system, with KAPPA
(Figure 2.6) being the energy constant of the potential.
2.1. Computational Methods 68
HILLS HEIGHT 2.0 W_STRIDE 2000
PRINT W_STRIDE 500
PTMETAD
WELLTEMPERED SIMTEMP 310 BIASFACTOR 5.0
###########################################
# CV DEFINITION
###########################################
#CV1 :
DISTANCE LIST <lys40> <asp150> SIGMA 0.03
UWALL CV 1 LIMIT 3.50 KAPPA 100.0
#CV2 : ring PHE151 e CB ILE62
DISTANCE LIST <phe151ring> 1006 SIGMA 0.03
UWALL CV 3 LIMIT 3.50 KAPPA 100.0
#CV3 : DFG dihedral combination
#phi ALA149: C ASP150: N CA C
#psi ASP150: N CA C PHE151: N
#psi LEU153: N CA C SER154: N
ALPHABETA NDIH 3 SIGMA 0.1
2438 2440 2442 2450 1.0
2440 2442 2450 2452 0.5
2479 2481 2496 2498 -0.5
#CV4 :
DISTANCE LIST <beta127_130> <beta154_157> SIGMA 0.03
UWALL CV 2 LIMIT 4.00 KAPPA 100.0
###########################################
# GROUP DEFINITIONS
###########################################
lys40->
647 650 653 656
lys40<-
asp150->
2447 2448 2449
asp150<-
beta127_130->
2077 2091 2111 2130
beta127_130<-
beta154_157->
2500 2511 2535 2556
beta154_157<-
phe151ring->
2459 2460 2462 2464 2466 2468
phe151ring<-
###########################################
ALIGN_ATOMS LIST <allused>
allused->
LOOP 640 2600 1
allused<-
##########################################	
1
atoms defining the center of mass 
of each residue or group of residues
t s fi i  t  c t r f ass 
f very residue or group of residues
Gaussians
method of choice
simulation temperature
residue center of mass
how often is saved the COLVAR file
Figure 2.6: Example of the PLUMED input file (version 1.3[163]) used to perform the PT-
metaD simulations described in this thesis. Highlighted in yellow are the parameters chosen
by the user. The numbering used for the residues defining the CVs do not correspond to the
2SRC.pdb numbering, used in Section 2.1.6, but to the original pdb file used in the simulation.
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2.1.8 PTmetaD analysis
Free energy surface reconstruction
The free energy surface (FES) of the PTmetaD simulations was reconstructed as a func-
tion of the biased CVs. The deposited energy bias along the trajectory was integrated
for the replica at 310K. The HILLS output file was given as input to the sum_hills post-
processing program, implemented in the PLUMED plugin[163]. In the HILLS file are
stored all the Gaussians deposited during the simulation for each CV. By specifying in
the command line of sum_hills the CVs to consider, the program integrates the added
bias over time, and it reconstructs the free energy as function of the selected CVs.
Checking the convergence of the free energy reconstruction
The convergence of free energy (FE) calculations is a serious concern of enhanced
sampling methods. In Metadynamics usually only when the system is able to diffuse
freely in the entire CV space and the variations in FE are minimum, the FE reconstruc-
tion is converged. The convergence of the FE can be monitored by reconstructing the
added bias (sum_hills) at regular intervals. If the FE variation is minimal (less than 1
kcal/mol) during the last 50 ns of simulation, the calculation is usually converged.
Mono-dimensional and bi-dimensional reconstruction of the FE, for the simula-
tions performed in this thesis, were obtained and checked for convergence. Only pro-
jections along CV1 (distance D404-K295) and CV2 (distance F405-L317/I293) are
shown throughout this thesis (see Results), because they are the two CVs that better
discriminate between the DFG-in and DFG-out conformation.
Free energy reweighting
The reweighting technique[185, 186] (performed with driver, the post-processing pro-
gram of PLUMED[163]) was used to monitor CVs not directly sampled during the
PTmetaD simulation. This is possible thanks to the enhanced sampling guaranteed by
the Parallel Tempering method[157]. All conformational changes happening on a faster
timescale than those described by the CVs, will be sampled as well during the simula-
tion, making their reweight possible later on. Thus, additional CVs could be chosen a
posteriori and their FE profile retrieved by reweighting the added bias.
The PTmetaD reweighting performed in the study was meant to investigate the
N-lobe dynamics in Src and Abl. The FE profiles were reweighted along four new CVs
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that describe the movements of the N-lobe loops and αC-helix. The selected distances
were (see Figure 2.7):
• CV5 = distance between residues <F278> of the P-loop and <P304> at the
N-terminal of the αC-helix
• CV6 = distance between residues <P304> of the αC-helix and <E331> of the
β2-β3 loop
• CV7 = distance between residues <K316> at the C-terminal of the αC-helix and
<M380> at the N-terminal of the αF-helix
• CV8 = distance between residues <K298> and <M302> both belonging to the
β3-αC loop
Figure 2.7: Collective variables chosen for the reweighting of the well-tempered PTmetaD
simulation for both Src and Abl (2SRC.pdb numbering considered). Figure taken from Ref
[187].
The second PTmetaD reweighting performed interests the resistant mutants of Abl
and the wild-type Abl and Src. It was meant to investigate the conformational change of
the activation loop, and in particular the population of the open conformation sampled
by the mutants. The FE profiles were reweighted along two path collective variables
describing the "open to close" path of the A-loop (Figure 2.8) and having as refer-
ence conformations the crystal structures of Src and Abl with A-loop open and closed
(2SRC.pdb (closed) and 1Y57.pdb (open) for Src; 1IEP.pdb (closed) and 2F4J.pdb
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(open) for Abl). CV1 corresponds to the A-loop path "open to close" in Src and CV2
to the A-loop path "open to close" in Abl.
Figure 2.8: Representation of the activation loop in the open (in red) and closed (in green)
conformations used as references in the PTmetaD reweighting of Src and Abl.
Structural analysis of the FES
The structural analysis of the PTmetaD simulations was performed extracting snapshots
from the trajectory corresponding to the FE minima and transition states of the free
energy surface (FES).
2.1.9 Limitations of the computational methods
As I have previuosly discussed, the main factors limiting the accuracy of MD simula-
tions are: the quality of the force-field used and the timescale problem[188]. Protein
force-fields trade accuracy for speed. The hydrogen bonds, for example, are described
as Coulomb interactions despite their quantum mechanical nature[189]. Moreover the
electrostatic and the van der Waals interactions are approximated. Polarizability is
not included and the Lennard-Jones potential is used to define dispersion forces[190].
However, the significant efforts made in the last years to include the missing terms in a
mean field average manner, make protein force-fields more accurate and reliable[191].
In a recent paper, Lindorff-Larsen et al.[132] compared the performance of sev-
eral recent force-fields in protein folding (see Figure2.9). The force-fields with the
lower score, and so with the higher agreement with experiments, are Amberff99SB*-
ILDN[128, 168] (applied in this thesis) and CHARMM22*[131].
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Figure 2.9: Improvement of force-fields accuracy over time. The force-fields with lower scores
are those showing a higher agreement with experiments. Figure taken from Ref [132].
With respect to the timescale problem, I have discussed the pros and cons
of enhanced-sampling methods. As nowadays it is still impractical to simulate
an entire protein domain for milliseconds, even using specialised hardware[118],
in order to study complex transitions the use of enhanced-sampling approaches is
necessary[145, 144].
2.2 Experimental Methods
For the purpose of this study, molecular biology and biophysical experiments were
performed to investigate the affinity of the drug imatinib towards engineered mutants
of the Src kinase. Mutations have been engineered on the basis of the computational
data retrieved in the work. The in vitro expression of Src and its mutants was set up to
perform isothermal titration calorimetry experiments (ITC).
2.2.1 In vitro protein expression
Traditionally, the expression of recombinant proteins is achieved by infecting cells with
a DNA vector, containing the template for the expression of the protein of interest. The
infected cells are then cultured and the transcription of the desired protein activated.
For these purposes, E.coli bacterial cells are widely used, because they are easy to cul-
ture and able to assure high protein yields[192]. Subsequently, the cells expressing the
recombinant protein are lysed and the protein extract is purified. The selection of cell
types (e.g. bacterial, mammalian, insect), growing medium (e.g. Luria Broth medium,
autoinduction medium, minimum medium) and growing conditions (temperature) de-
pend on the desired yield and type of recombinant protein to express[192].
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In the present work E.coli strain BL21(DE3) cells were used. The plasmid en-
coded for the unphosphorylated form of Src kinase domain (supplemented with an
hexahistidine tag followed by a TEV protease cleavage site used for purification pur-
poses), plus for the YopH phosphatase and the chaperone pG-KJE8 (Takara), encoding
for groESL proteins. The co-expression of Src KD together with phosphatase[20] and
chaperones[193] was meant to obtain unphosphorylated and properly folded protein,
respectively[194]. The same construct was used also for the expression of the resistant
mutants of Src.
2.2.2 Protein purification
Chromatography is one of the most widely used means to achieve the separation of
individual proteins from protein mixtures. The choice of the chromatography tech-
niques to adopt in the design of a purification protocol may vary. The choice is usu-
ally based on the physical and chemical properties of the recombinant protein to iso-
late. The purification protocol is carefully tailored for every protein. In fact, what
could be successfully used to purify one protein, might determine the inactivation of
another[195, 196, 197, 198].
In practical terms, the protein extract (also called surnatant), obtained after cells
lysis, is loaded onto the chromatography column. General properties of proteins, such
as charge, size or specific interactions with engineered protein tags, are exploited in
the separation process. The chromatography columns are composed of a packed matrix
(e.g. agarose, silica, dextran), called the stationary phase. Loaded onto the column and
moving throughout it are the eluents, i.e. the mobile phase, such as the protein mixtures
and the buffers.
Different chromatography techniques are available[195, 196, 198]. A common
mechanism, used in affinity and ion-exchange chromatography, is characterised by a
first selective capturing step, where the protein of interest binds to the stationary phase,
while impurities are washed away by the eluent. Subsequently, the conditions favouring
the binding are changed, so that the protein is finally eluted[195]. The mechanism just
described is illustrated in Figure 2.10, example of a chromatogram profile generated
during a purification process. However, an exception to this method is size exclusion
or gel filtration chromatography, where the protein of interest is separated based on its
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size (molecular weight)[195, 196].
Figure 2.10: Example of the chromatogram generated by affinity and ion-exchange chromatog-
raphy method. During purification the solution, before being collected, passes through an UV
detector. Thus, the UV absorbance profile is monitored to check for protein concentration. Af-
ter loading the sample into the column (load phase, no UV signal), the protein of interest will
bind to the column, while all the impurities will be eluted, determining the increase of the UV
signal. It follows a wash phase to eliminate all impurities, and only when the UV profile has re-
turned to baseline, the conditions will be modified to determine the elution of the target protein
(elution phase, UV peak). Figure taken from Ref [199].
Affinity chromatography
Affinity chromatography exploits the formation of hydrogen bonds, electrostatic and
van der Waals interactions, which are involved in many binding processes, for the sep-
aration of proteins[200, 196, 198].
The matrix of the chromatographic column is supplemented with a specific ligand,
covalently bound to the matrix and proved to have high affinity for the target protein.
When the sample containing the protein mixture is loaded onto the column, the protein
of interest binds, reversibly, to the ligand. Thus, while the other proteins will be washed
away by the continuos elution of buffer, the target protein will remain stuck to the
column. The subsequent change in the conditions of the loaded buffer will weaken the
protein-ligand binding thus, causing protein elution.
In this study the chromatographic column used was the HisTrap HP nickel column
(GE Healthcare). The column was supplemented with nickel (the ligand) while, as
mentioned in Section 2.2.1, a hexahistidine tag (His-tag) was engineeringly attached
to the kinase domain of Src and of the mutants. The His-tag has a high affinity for
nickel and thus Src will remain initially stuck to the column. Only when a imidazole
rich buffer is loaded, Src dissociates and is eluted (histidine has higher affinity for
2.2. Experimental Methods 75
imidazole than for nickel).
Ion-exchange chromatography
Ion-exchange chromatography bases its separation strength on differences in protein
surface charges. The protein of interest could interact with a positively or negatively
charged stationary phase, depending on the protein surface charge (see Figure 2.11).
The elution of the protein is mediated by changes in the pH or in the ionic strength of
the buffer[195, 196, 198].
Figure 2.11: Ion-exchange chromatography. The matrix is negatively charged (grey beads).
Positively charged proteins (blue beads) interacts with the matrix and are retained, while nega-
tively charged proteins (pink beads) are eluted. Figure taken from Ref [201].
In this study the Ion-exchange chromatographic column used was the Q anion
exchange column (GE Healthcare). The elution of the target protein was obtained by
changing the ionic strength of the buffer. Once the protein was stuck to the column,
a buffer with high concentration of NaCl was loaded. These ions compete with the
protein to interact with the matrix and thus, the stronger is the protein charge the higher
should be the salt concentration needed.
In ion-exchange chromatography, as well as in affinity chromatography, buffer
changes were performed by gradient elution. Let’s consider buffer A as the buffer
favouring the binding of the protein to the column, and buffer B the one disfavouring
the binding. The gradient guarantees not to have a sudden change between buffers, but
to have a progressive increase of buffer B over buffer A, till reaching 100% of buffer B
at the end of the gradient.
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Size-exclusion or gel filtration chromatography
As previously mentioned (see Section 2.2.2), size-exclusion chromatography separates
proteins according to their size. The column matrix does not have any bound ligand,
but it is just constituted of porous particles[195, 196, 198]. The porous dimension could
be chosen accordingly to the molecular weight of the target protein, in order to obtain
a good separation among the protein mixture. The column used in the study was a
Superdex 75 16/60 size-exclusion column (GE Healthcare).
Proteins, based on their size, can follow an easier or more difficult pathway
throughout the column. Bigger size proteins, for steric reasons, will be eluted first
because they are excluded from the column matrix, while smaller proteins will be re-
tained longer in the intricate maze of the column matrix, delaying their elution[195]
(see Figure 2.12).
Figure 2.12: Size-exclusion chromatography. Large proteins are excluded by the column beads,
while small proteins are retained and eluted later. Figure taken from Ref [202].
2.2.3 Expression and purification of Src wild-type and Src
engineered mutants
Expression of Src wild-type for isothermal titration calorimetry
Src KD was expressed and purified following the procedure published in Ref [194] with
two exceptions regarding the labelling of the protein and the affinity tag cleavage, both
avoided since not crucial for ITC experiments (see Figure 2.13).
The E.coli cells were grown at 37◦C in 1 litre of Luria Broth standard medium,
containing the specified amounts of antibiotics: 50 µg/ml of kanamicin, 50 µg/ml of
streptomycin and 20 µg/ml of chloramphenicol, for Src KD and YopH plasmid se-
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lection and 5 ng/ml of tetracyclin, for continuous induction of chaperones expression.
Reached the optical density (OD600) of∼0.8, protein expression was induced by adding
to the cell culture 0.2 mM of IPTG, the temperature was lowered at 20◦C and cells were
left growing overnight.
Expression of Src engineered mutants for isothermal titration calorimetry
The same expression protocol of Src WT was successfully used for the production
of the engineered αG mutant (Q275A/P299Q/V461S) of Src. Due to protein solubil-
ity problems, a new protocol (see Figure 2.13) was established for the expression of
the other mutants (Q275A/P299Q/Q420E, Q275G/P299E/Q420A and αC-chimera).
In the new protocol, cells were grown at 37◦C in 1 litre ZYP-5052 autoinduction
medium[203], supplied with antibiotics (for quantities see previous Section). At OD600
∼0.8, temperature was lowered at 16◦C and expression was allowed for 48 h, to reach
a good bacterial expression. The adoption of the autoinduction medium together with
the change in temperature (from 20◦C to 16◦C), were found to be crucial for a proper
expression of the Src mutants, because the slow cell growth assured the correct folding
of the protein, avoiding precipitation.
Purification protocol for isothermal titration calorimetry
The cell culture expressing the protein was centrifuged at 4000 rpm for 15 minutes
at 4◦C. The pellet was resuspended with buffer (50 mM Tris pH 8, 500 mM NaCl,
25 mM Imidazole and 5% Glycerol) and it was sonicated on ice (instrument settings:
37% power, 3 seconds on and 1 second off pulser for a total of 10 minutes). The soni-
cated sample was then centrifuged at 40000 rpm for 40 minutes at 4◦C. The surnatant,
containing the protein of interest, is now ready for purification.
A new two-step purification protocol was developed in the work presented in this
thesis (see Figure 2.13). It allows one to obtain greater yields of high quality proteins
(needed for ITC experiments) and to reduce the experimental time needed (1 day long
purification). After sonication, the surnatant was loaded on the HisTrap HP nickel col-
umn (GE Healthcare) and the protein was eluted with a linear gradient of 0-100% of
elution buffer (50 mM Tris pH 8, 500 mM NaCl, 500 mM Imidazole and 5% Glyc-
erol). This first purification step is a rough separation made with a nickel column,
through affinity chromatography. The protein construct was supplied of an His-tag
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Figure 2.13: Schematic workflow of the protocols used for the expression and purification of
Src WT and the engineered mutants of Src. In red are highlighted the changes made to the
original protocol of Ref [194].
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(hexahistidine tail) with an high affinity for nickel but even higher for imidazole. When
the protein passes through the HisTrap column, it remains stuck and only when the
imidazole rich buffer is loaded, the protein can be eluted.
The recollected fractions from the HisTrap column with the target protein were
then loaded onto a Superdex 75 16/60 size-exclusion column (GE Healthcare), equi-
librated with a buffer composed of 20 mM Tris pH 8, 0.5 mM NaCl, 1 mM MgCl2
and 1 mM TCEP. The second purification step permits to obtain a pure product, since
separation of proteins on the size-exclusion column (S75) happens by means of their
molecular weights.
The simplified protocol skips two of the four steps of Ref [194] (see Figure 2.13):
the Q column and the TEV-cleavage. Both were avoided because they cause a huge
loss in protein yields. Moreover, the TEV cleavage was not needed, since the presence
of the His-Tag is not detrimental for ITC experiments. A further implementation to the
protocol was necessary given the high instability shown by the engineered mutants of
Src at room temperature (Tr). Thus, the entire purification was carried out in a cold
room at 4◦C.
2.2.4 Isothermal titration calorimetry
The study of the binding between a ligand and its substrate could be done by means of
different experimental techniques: fluorescence assays, NMR, surface plasmon reso-
nance (SPR) and isothermal titration calorimetry (ITC). ITC is one of the most widely
used techniques in drug discovery[204]. The absence of probes (as in fluorescence),
of temperature, molecular weight and pH limitations (as in NMR) and neither the need
to immobilise the substrate (as in SPR), are all advantages rendering ITC assays very
straightforward and reduced in costs. However, the large amount of sample needed
and the low sensitivity of the instrument for nM binding range, are the reasons why
sometimes ITC is not the best choice. Nevertheless, the advantage of using this tech-
nique is the possibility to rapidly recover the thermodynamics of the binding process
of interest[205, 206]. In this study, ITC experiments were performed to determine the
affinity of imatinib for Src WT kinase and for the engineered mutants of Src.
The instrument is constituted of two cells (see Figure 2.14). The sample cell, that
is filled with the substrate in solution (Src), and the reference cell, filled with water
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and maintained at a constant temperature. During the experiment, the solution of the
ligand (imatinib) is titrated with a syringe into the sample cell. The binding event of
the ligand with the substrate will produce, or not, heat (exothermic or endothermic
reaction). Changes in temperatures between the cells are detected by the instrument.
The quantification of the heat produced by the binding events, derives by the power
needed to maintain the two cells at the same temperature (∆T =0).
Figure 2.14: Schematic representation of an ITC instrument. Figure taken from Ref [207].
A graphical representation of the titration is created in real time, with peaks re-
ferring to the variation in power (µcal) over time. The area under the peaks is then
integrated to recover the enthalpy corresponding to the binding event (see Figure 2.15).
The heat (kcal/mol) derived from the formation of the protein-imatinib complex, in
function of the molar ratio of the ligand, produces the isothermal curve, whose slope
corresponds to the dissociation constant, Kd (see Figure 2.15). The ITC experiment
permits to directly retrieve the binding affinity (Ka =1/Kd), the enthalpy (∆H) and the
stoichiometry (n) of the binding event under analysis. Moreover, given the relationship:
∆G =−RT lnKa = ∆H−T∆S (2.10)
the variation in the free energy of binding (∆G) and in entropy (∆S) could be recovered
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as well.
Figure 2.15: Example of the outputs produced during an ITC experiment. Figure taken from
Ref [208].
Particularly important for the accuracy of the results is for the two solutions, the
one with the substrate and the one with the ligand, to be identical. The thermodynamic
parameters, for the binding of imatinib to Src WT and to the engineered mutants of Src,
were acquired using a VP-ITC microcalorimeter (MicroCal Inc.).
Sample preparation for ITC experiments
The purified protein was dialysed over night in buffer MES with pH 6.5 (50 mM MES,
500 mM NaCl, 1 mM EDTA, 5 % (v/v) Glycerol). Protein concentration was deter-
mined by NanoDrop 1000 spectrophotometer (λ=280 nm) and immediately used to
perform the experiment.
ITC essay details
The protocol for the ITC experiment of Src is inspired by the work collected in the
doctoral thesis of Dr Ralitza Boubeva[209]. Some changes have been introduced to
improve the experiment accuracy.
The sample solution consisted of 2 ml 0.1 mM protein in MES buffer (pH 6.5) and
supplemented with 2% DMSO. The ligand solution consisted of 2 ml 1.6 mM imatinib
in MES buffer, at the same pH and with 2% DMSO. Both solutions were degassed
for 5 minutes under vacuum. Titrations were conducted at 30◦C and consisted of a
first control injection of 2 µl followed by 37 injections, of 8 µl and 16s duration each,
spaced by an equilibration period of 480s. The sample during the measurement was
stirred at 266 rpm. Raw data were collected and corrected for ligand heats of dilution. A
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one site binding model was assumed and data were fit using MicroCal Origin software
(version 7.00). All the experiments were repeated in triplicate.
Thank to the 1 day long purification protocol it was possible the use of fresh pro-
tein for ITC experiments, assuring an high percentage of protein binding sites avail-
ability, increasing the quality and reliability of the essay.
Chapter 3
The different flexibility of Src and Abl
kinases regulates the accessibility of
the DFG-out conformation
In this Chapter, the two TKs Src and Abl are investigated in great detail, to unveil the
reasons underlying the different affinity towards the anti-cancer drug imatinib. As dis-
cussed in the Introduction (see Section 1.4.1), Abl is imatinib primary target (IC50=0.2
µM), while Src is weakly inhibited by the drug (IC50>100 µM), despite the 45% se-
quence identity[65] and the presence of crystal structures showing imatinib binding to
both kinases[20].
Src and Abl can adopt the druggable DFG-out conformation, and the correspond-
ing crystal structures show no major differences between their binding interactions with
imatinib[78] (see Introduction, Section 1.4.2). It has been proposed that the binding
of imatinib follows a conformational selection mechanism[78, 81] (see Section 1.4.2).
Therefore, it could be hypothesised that the kinetics and/or thermodynamics of the con-
formational transitions leading to the DFG flip (conformational change from DFG-in
to DFG-out) may determine the affinity to imatinib of a specific kinase.
To test these hypotheses, the DFG flip was studied for both Abl and Src, by means
of massive molecular dynamics simulations (MD) and free energy calculations (PT-
metaD). Given the complex nature of the conformational change analysed (DFG flip),
long classical MD simulations (1 µs long) were not sufficient to obtain a satisfactory
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sampling of the DFG transition. Thus, the use of advanced methods (PTmetaD), able
to enhance the sampling of slow conformational changes, was essential.
The results reported below point out crucial differences in the accessibility and
stability of the DFG-out conformation of Src and Abl, ascribable to structural and dy-
namical features proper of the Abl kinase domain (KD). These peculiarities in both
the sub-µs dynamics and conformational dynamics of Abl could be responsible for the
higher imatinib activity reported for Abl.
3.1 Classical MD simulations and RMSF analysis of
Src and Abl
Classical 1 µs long MD simulations were performed using as starting structures the
DFG-in active conformation of Abl and Src kinase domain (see MD details Section
2.1.4). Classical MD simulations were extensively exploited to study the essential dy-
namics (sub-µs dynamics and dominant motions) of TKs.
To investigate the sub-µs dynamics (pico to nanosecond timescale) of Src and Abl,
the root mean square fluctuation analysis (RMSF, see Materials and Methods, Section
2.1.5) was used. The RMSF analysis performed on the MD trajectories reveals differ-
ent flexibility patterns in the sub-µs dynamics for the two proteins. Higher average
fluctuations were observed for Abl with respect to Src, especially in the N-lobe loops
(P-loop, β2-β3 loop and β3-αC loop) and in the A-loop. The only exception was the
αG-helix region, more flexible in Src (see Figure 3.1). All the mentioned areas, which
show significant differences in RMSF between both systems, are involved in crucial
conformational changes linked to the DFG flip[17].
The analysis of the MD trajectories shows a peculiar conformation of the αC-helix
region that differs in the two structures. The αC-helix of Abl experiences an upwards
movement (see Figure 3.2). This movement could be relevant, not only because the
αC-helix is involved in the DFG-in to DFG-out switch, but also because of its vicinity
to the binding site, where imatinib docks.
In order to characterise this conformational change in more detail, the distances
between the Phe405 of the DFG motif and the αC-helix residue Leu317 in Src and
Ile293 in Abl, were monitored (2SRC.pdb numbering used). These two residues
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Figure 3.1: (A) RMSF profiles of the Cα atoms of Src (in green) and Abl (in red). (B) RMSF
analysis representation directly on the structures of Abl and Src. The thickness of the ribbon
is proportional to the RMSF magnitude. The colour spectrum ranges from more rigid (blue) to
more flexible (red). Figure taken from Ref [187].
Figure 3.2: Conformations adopted by the αC-helix of Src (in green) and Abl (in red). The
distances F405-L317 in Src and F405-I293 in Abl (residues shown in sticks) were monitored to
characterise the αC-helix movement.
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(Phe405 and Leu317/Ile293) belong to the allosteric pocket of the active site, and are
also part of the regulatory hydrophobic spine (R-spine, see Introduction 1.2.2)[23, 22]
thus, involved in the regulatory network of the kinase.
In Src, the mean distance between the residues (considering the Cζ atom of Phe405
and the Cβ atom of Leu317) fluctuates around a value of 4.6 ± 0.4 Å, while in Abl it
reaches a larger average of 5.2 ± 0.6 Å (see Figure 3.3). The significant increase in
the distance reached by Abl (with maximum up to 8.5 Å) is due to a side-chain flip
of residue Ile293 (see Figure 3.2). From the trajectory, it could be seen that the side
chain briefly jumps from its usual "in" conformation, facing the Phe405 of the DFG
motif, to an "out" conformation pointing away from the hydrophobic pocket. During
the 1 µs trajectory, the reorientation of the αC-helix occurs with a period of 500 ns
and a lifetime of 30 ns, while the flip of the Ile293 occurs approximately every 70 ns
and has a lifetime of 200 ps. None of the two events have been observed in Src, where
the αC-helix is much more stable and the orientation of the Leu317 side-chain remains
unchanged for the duration of the whole simulation.
In summary, significant differences between Src and Abl sub-µs dynamics were
found, with Abl showing a higher degree of flexibility. Moreover, the observed reori-
entation of both the αC-helix and residue Ile293 could favour the adoption of multiple
conformations in Abl not accessible to Src.
3.2 PTmetaD calculation and free energy surface
reconstruction
The observed changes in the dynamics of structural motifs surrounding the active site,
prompted me to carry out a detailed and quantitative characterisation of the energet-
ics of the DFG-flip, by means of well-tempered PTmetaD method. The choice of the
collective variables (CVs) is of pivotal importance to assure a good sampling (see Ma-
terials and Methods, Section 2.1.3).
In order to sample the DFG-flip transition (DFG-in to DFG-out) four CVs able to
discriminate between the two conformations were chosen (see Materials and Methods,
Figure 2.4). In brief, three CVs involve residues of the DFG motif (CV1= distance
<Asp404>-<Lys295>, CV2 = distance <F405>-<L317> for Src/I293 for Abl and
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Figure 3.3: (A) Distances Phe-Leu of Src (in green) and Phe-Ile of Abl (in red) were monitored
over the 1 µs long simulation. (B) Distribution of Src and Abl populations as function of the
residue pair distance. Figure taken from Ref [187].
CV3 = a DFG dihedral combination), and the forth the N-terminal region of the A-
loop (CV4 = distance <N381,...,H384>-<A408,...,I411>). The free energy surfaces
(FESs) of Abl and Src have been reconstructed as a function of two CV1 and CV2,
because those allowing a better sampling of the DFG flip transition.
Both simulations converged after 400 ns, as shown by the 1-D projection over time
of CV1 and CV2 in Figure 3.4. Our choice of CVs resulted in FES where the DFG-in
and DFG-out minima could be clearly distinguished (see Figure 3.5).
In both kinases the DFG-in conformation results to be the main minimum of the
FES, identifying the more stable and populated conformation of basins 1 and 4 in Figure
3.5 for Src and Abl, respectively. The second more stable and pronounced minimum is
the one corresponding to the DFG-out conformation (basins 3 and 8 in Figure 3.5). The
free energy difference between the two conformations is 4.0± 0.5 kcal/mol for Abl and
3.2. PTmetaD calculation and free energy surface reconstruction 88
Figure 3.4: 1-D projection over time of the free-energy basins of CV1 (A) and CV2 (B) of Abl
and Src (C, D). Figure taken from Ref [187].
6.0± 0.5 kcal/mol for Src. Thus, the DFG-out conformation in Abl is 2 kcal/mol more
stable with respect to Src. Another important element differentiating the two FESs is
the height of the energy barrier separating the two conformations, lower in Abl (6 ±
0.5 kcal/mol) than in Src (11 ± 0.5 kcal/mol).
The FES of Abl displays a third local minimum (basin 6 in Figure 3.5), just 1
kcal/mol higher than the DFG-out state. This minimum corresponds to an intermediate
conformation in which the Asp404 is pointing downward (see structure 6 in Figure
3.5). This peculiar "Asp-down" conformation was first reported in the work of Shan et
al.[70]. In total contrast, the corresponding area on the FES of Src exhibits a transition
state instead of a minimum (state 2* in Figure 3.5). In the FES of Abl, the DFG-in
and DFG-out conformations are connected via the "Asp-down" conformation and two
transition states (5* and 7* in Figure 3.5). Thus, it is clear that the DFG flip mechanism
taking place in Abl is significantly different from that of Src.
Furthermore, the local minima in the FES of Abl appear to be wider compared to
Src, particularly the DFG-out minimum along CV2 (15-19 Å). This is a hint of a major
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Figure 3.5: (A) Reconstructed FESs of Src (left) and Abl (right). The error on the minima
and barriers of the FESs amounts to 0.5 kcal/mol. (B) Structures corresponding to the relevant
minima and transition states. Figure taken from Ref [187].
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structural plasticity along this variable. Thus, I extracted snapshots from the trajec-
tory corresponding to the FE minima (for details see Section 2.1.8) and analysed their
conformational features. The higher values reached by Abl along CV2, the Phe-Ile
distance, are due to conformational changes in the αC-helix and in the orientation of
residue Ile293 (structure 8 in Figure 3.5 and Figure 3.6). These results are in agreement
with what previously observed, in the classical MD simulations, such as the higher val-
ues for the Phe-Ile distance and the Ile293 "flip". The enhanced flexibility of Abl has
its distinctive mark along the Phe-Ile distance (CV2) while, the values of CV1 are com-
parable to Src. Thus, Abl has not only a more stable DFG-out druggable conformation,
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Figure 3.6: (A) Free energy profiles projected along CV2, distance Phe-Leu in green for Src
and Phe-Ile in red for Abl. The green and red bars indicate the width of the respective minimum
(B) Conformations adopted by the αC-helix of Src (in green) and Abl (in red), corresponding
to the local energy minimum indicated with a green and red star, respectively, in panel A.
but also a lower barrier to overcome for the DFG flip to happen. Likely, the structural
plasticity exhibited by Abl could have a major impact in lowering the height of the
energy barrier.
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3.3 Free energy reweighting
The higher flexibility and conformational changes identified in the N-lobe loops, αC-
helix and A-loop region of Abl could result in a widening of the active site when adopt-
ing the DFG-out conformation (see Figure 3.7). A wider active site could favour the
binding of imatinib to Abl, with respect to Src, facilitating drug engagement and min-
imising steric clashes.
To characterise in detail the conformational dynamics of the areas surrounding
the active site, the reweighting technique was used to reprocess the free energy of Src
and Abl, along four new CVs. The new CVs, not directly considered in the original
PTmetaD simulations, described the movements of the N-lobe loops and αC-helix (see
Materials and Methods, Section 2.1.8 and Figure 3.8, image A). The reweighted 1-D
free energy profiles (see Figure 3.8) proved that, along all the new CVs, Abl explores
a wider conformational space, with respect to Src, confirming its intrinsic structural
plasticity.
Figure 3.7: Alignment of structures extracted from the PTmetaD minima (DFG-in and DFG-
out). Changes in the N-lobe loops and αC-helix conformations of Abl (in red) can be appreci-
ated in the passage from DFG-in to DFG-out while, slight differences can be detected for Src
(in green).
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Figure 3.8: (A) Reweighting CVs (only Src numbering used). (B) 1-D projections of the
reweighted FE profiles for Src (in green) and Abl (in red). The green and red bars underline the
minima of Src and Abl, respectively. The error on the minima and barriers of the FESs amounts
to 0.5 kcal/mol. Figure taken from Ref [187].
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3.4 Solvent accessible surface area and water
accessibility
The analyses of the classical MD and PTmetaD trajectories suggest that the active site
of Abl opens up dynamically during the fluctuations of Abl in solution.
To address the hypothesis of a wider binding site in Abl than Src, the solvent
accessible surface area (SAS) of the binding sites of both kinases was calculated (for
details see Section 2.1.5). In the DFG-in conformation, the SAS is 5900 ± 200 Å2 in
Src and 6000 ± 100 Å2 in Abl. In the DFG-out conformation, the active site in Src
remains unaffected by the DFG flip (SAS = 5900 ± 100 Å2) while in Abl the average
size of the cavity increases to 6200 ± 200 Å2 (see Figure 3.9).
The enlargement of the active site in the DFG-out conformation of Abl (Figure
3.9) should lead to an increase number of water molecules found in the vicinity of the
DFG motif. To perform the count of water molecules within 5 Å of the DFG residues,
Figure 3.9: Comparison of the cavity dimensions in the DFG-in and DFG-out conformations
of Src (in green) and Abl (in red).
new MD simulations of 20 ns each for the DFG-in and DFG-out of Src and Abl were
performed (see Section 2.1.5). In Src the number of water molecules remains unaf-
fected in both conformations (19 ± 3). In comparison, the averaged number of water
molecules in Abl is increased due to the entrance in the cavity of up to three addi-
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tional water molecules in the DFG-out conformation (19 ± 5 in the DFG-in; 22 ± 5 in
the DFG-out). In Abl, the additional water molecules surrounding the Asp404 residue
could contribute to the stabilisation of the inactive conformation, thanks to a more
favourable environment and the formation of hydrogen bonds (see Figure 3.10).
 DFG-in DFG-out
F405
D404
F405
D404
Figure 3.10: Water molecules within 5 Å of the DFG motif of Abl (shown in sticks) in the
DFG-in and DFG-out conformation.
3.5 Calculation of the pKa and influence of Asp404
protonation
As discussed in the Introduction (see Section 1.4.1), the binding of imatinib to Abl was
proposed to be pH dependent. This might be due to variation in the pKa of residue
Asp404 in the DFG-in and DFG-out conformation[70]. To quantify the contribution of
pH to the flip, the pKa of the Asp404 residue was calculated for the DFG-in and out
conformations in both kinases. The average pKa values for Abl were 3.4 and 4.4 for
the DFG-in and DFG-out, respectively, meaning a positive contribution to the ∆G of
the transition (∆∆Gin−out = 1.4 ± 0.9 kcal/mol). In the case of Src, the average pKa
were 4 in the DFG-in and 2.6 in the DFG-out. Therefore, the adoption of the DFG-out
conformation is destabilised by almost 2.0 ± 0.9 kcal/mol.
3.6 Discussion
The DFG-out imatinib-binding conformation is not only energetically more stable in
Abl than in Src, but the kinetics of the DFG transition is also more favourable due to
a lower free-energy barrier to cross. This is in agreement with the IC50 experiments
that proved imatinib to be a strong inhibitor of Abl but not of Src[65]. The better
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accessibility of the DFG-out conformation could be associated with a higher plasticity
of the Abl structure, as seen by the analysis of the sub-µs dynamics.
Furthermore, in Abl, Asp404 is more solvent exposed in the DFG-out conforma-
tion, compared to Src, due to reorientation of the αC-helix and enlargement of the
binding site. This conformation facilitates the entry of additional water molecules into
the cavity and thus stabilises Asp404. Moreover, it may also facilitate the entry of
imatinib into the cavity.
The pKa analysis shows a pH dependence of the binding of imatinb as well as of
the DFG-out population. At physiological pH (cytosol 7.2), according to the calculated
pKa values, the Asp404 of both kinases would be in the deprotonated form, thus dras-
tically reducing the population of the DFG-out in Abl (pKa DFG-out = 4.4) and even
more in Src (Ka DFG-out = 2.6).
Overall, the differences in the kinetics and thermodynamics of the DFG transi-
tion can explain the different imatinib activity towards Src and Abl, also confirming a
conformational selection binding mechanism of imatinib[187, 210, 211].
Chapter 4
The correlation of sub-µs dynamics to
drug binding in tyrosine kinases
In the previous chapter, the sub-µs dynamics was seen to influence the conformational
dynamics related to the DFG flip transition of Abl and Src. The greater flexibility
shown by the Abl kinase domain (KD) seems not only to facilitate the adoption of the
druggable conformation, but also to increase the size of the binding site in the DFG-
out. Together these effects could positively affect the binding of the drug imatinib and
explain its higher affinity for Abl.
To further confirm the relation existing between the sub-µs dynamics of the ty-
rosine KD and the imatinib activity, in this chapter I have extended the analysis of
the sub-µs dynamics to a larger pool of tyrosine kinases. As discussed in the Intro-
duction (Section 1.4.1), imatinib is not so selective as it was initially thought[61]. It
effectively inhibits several TKs, making it useful in the treatment of several cancers
beyond chronic myeloid leukemia (such as gastrointestinal stromal tumour (GST) and
metastatic tumours)[212]. However, imatinib also bind to other TKs but showing very
reduced activity[212].
Classical molecular dynamics simulations (MD) of several TKs were performed.
The TKs included in the study were chosen on the basis of their sequence homology to
Src and Abl, and of their different sensitivity towards imatinib (measured by IC50).
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4.1 Selection of the tyrosine kinases included in the
study
The selected TKs share at least 45% sequence identity to both Src and Abl, and they
are inhibited by imatinib with varying strengths (refer to Table 1.1 of the Introduction).
They are: Kit (IC50=0.31 µM[63]), Lck (IC50=9 µM[56]), Met and EGFR (IC50>100
µM[65, 66]). The IC50 is a quantitative measure of how effective is a drug. Higher is
the IC50, lower is the inhibitory effect, activity, of the drug. It is a measure of the drug
concentration needed to inhibit 50% of the substrate available.
Kit is the most sensitive kinase to imatinib after Abl, while Lck shows a discrete
sensitivity despite the huge sequence identity to Src (up to 70%). On the contrary, both
Met and EGFR are not effectively inhibited by imatinib even if, as in the case of Src,
they can adopt inactive DFG-out conformations and imatinib shows the same binding
mode as seen for Abl[64, 65, 66, 60, 64, 63, 56].
4.2 Allosteric coupling analysis
As discussed in Section 1.2.1, tyrosine kinases are characterised by a flexible struc-
ture, which is subject to significant conformational changes involving several conserved
structural elements. The concerted motions of these elements, leading to the adoption
of different conformations, require some degree of correlation.
To start understanding the allosteric connection of remote sites of the KD to the
binding site, I used a normal modes analysis approach (NMA) combined with a first-
order perturbation theory[178, 180] (see Section 2.1.5). The resulting allosteric cou-
pling maps are shown in Figure 4.1.
A high cross-correlation of the N-lobe β elements and loops (res. 1-45 in Fig-
ure 4.1) is observed in all kinases, as a consequence of the stable β -sheet secondary
structure. Only for a subset of them, namely Lck, EGFR and to a lesser extent Kit
and Met, this network is extended to include the αC-helix and the preceding β3-αC
loop (res. 45- 60 in Figure 4.1). These kinases (Lck, EGFR, Kit and Met) are also
the ones exhibiting a much higher correlation between the smaller β4-β5 hairpin (res.
70-80 in Figure 4.1) and the rest of the N-lobe. The central region (res. 80-150 in
Figure 4.1), encompassing the linker between the N-lobe and the C-lobe and part of
4.2. Allosteric coupling analysis 98
Src Met EGFR
Abl Kit Lck
Figure 4.1: Allosteric coupling maps of Src, Abl and the homologous TKs together with the
structure of the kinase domain with highlighted the elements involved in the allosteric coupling.
In the maps, the A-loop region corresponds to the area included in the white dashed lines. Figure
taken from Ref [93].
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the hydrophobic ATP binding pocket, shows negligible couplings with other structural
elements.
Interestingly, inter-lobe couplings are observed for the activation loop (res. 150-
170 in Figure 4.1). The A-loop plays a key role in the conformational changes occurring
in TKs[73, 17], and is involved in the transition from the active (A-loop open) to the
inactive conformation, in which the loop is predominantly closed. Abl shows a strong
correlation between the A-loop, the αC-helix, the P-loop and all the N-lobe loops in
general. This network is less prominent, but still present, in the other kinases analysed,
as Src, Kit and EGFR. In the case of Src, the A-loop movement results mainly coupled
with the αC-helix and the preceding loop. Conversely, Lck and Met show particularly
poor couplings for the A-loop (see Figure 4.1). The main element of the C-lobe in-
volved in allosteric coupling is the αG-helix, showing a correlation with the A-loop
movement in all kinases. This correlation is particularly prominent in Kit and EGFR,
where it extends partially to the N-lobe as well (see Figure 4.1).
Taken together, the allosteric coupling analysis predicts a highly correlated N-
lobe, where many structural elements move in unison, and a less correlated C-lobe,
where only the A-loop and the αG-helix emerge as correlated. What is more, the few
non-trivial inter-lobe correlations all involve the A-loop, whose motion appear as the
cornerstone of the large-scale allosteric connections in the kinases network, leading
inter-lobe movements. The analysis not only confirms TKs as proteins characterised
by a complex allosteric network[17, 15], but also identifies Abl as the kinase with the
greater correlation among all the structural elements important for the protein confor-
mational changes.
4.3 Classical MD simulations and RMSF analysis of
the homologous TKs
Long atomistic MD simulations were performed for all the kinase domains (KD) of the
chosen TKs, adopting the DFG-in conformation (see Section 2.1.4). To investigate the
sub-µs dynamics of the homologous TKs, with respect to Src and Abl, the root mean
square fluctuation analysis (RMSF) was performed (see Section 2.1.5). As it can be
seen in Figure 4.2 (bottom panels), the N-lobe loops and the A-loop are confirmed as
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Figure 4.2: (a) RMSF profiles of Src (blue) and Abl (red). Grey panels identify the N-lobe and
the A-loop region. (b) RMSF profiles of the homologous TKs. In the two panels are reported
the RMSF profiles of the N-lobe region (left) and A-loop region (right), being the areas whose
flexibility varies most among the pool of TKs. Shades of red identify the flexible TKs, shades
of blue the more rigid ones. Dotted lines are used for clarity. Figure taken from Ref [93].
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the most variable regions of the structure, also in the homologous TKs.
For what concerns the A-loop, Lck and Kit reach or even exceed the RMSF values
registered for Abl (peaks at 4.2 Å, 3.0 Å and 5.5 Å for Abl, Lck and Kit, respectively,
see Figure 4.2), while Met and EGFR have a more rigid profile in this region, more
similar to the one observed for Src (RMSF values of 2.0 Å, 2.6 Å and 2.5 Å for Src,
Met and EGFR, respectively, see Figure 4.2). Looking at the N-lobe region, again Src
has the most rigid profile, due to an RMSF value of the N-lobe that never exceeds 1.5
Å. Higher values are observed for Abl, Lck and Kit, in a range that goes from 1.8 Å to
3.2 Å (see Figure 4.2). Surprisingly, Met and EGFR report the highest RMSF values in
the N-lobe, above 2.5 Å (Figure 4.2). In the αG-helix region (see Figure 4.3), EGFR is
the only TK showing a flexibility comparable to the one of Src (2.0 Å).
Figure 4.3: RMSF profile of the αG-helix of Src, Abl and the homologous TKs. Shades of red
identify the flexible TKs, shades of blue the more rigid ones. Dotted lines are used for clarity.
Figure taken from Ref [93].
While the flexibility of the N-lobe seems to vary across all kinases without a par-
ticular apparent trend, there is a remarkable (anti)correlation between the A-loop flexi-
bility and the imatinib IC50 (see Table 4.1). The kinases having the most flexible A-loop
(Abl, Kit and Lck) are also the ones with the lowest IC50 value, meaning that imatinib
is able to efficiently inhibit the kinase. On the contrary, the kinases with a lower RMSF
in the A-loop show a higher IC50 in the literature.
The N-lobe and the A-loop are known to be involved in the conformational
changes leading to the adoption of the druggable, DFG-out, conformation[20]. The
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higher flexibility of both these regions, as in Kit and Lck, could facilitate the kinase
conformational transition (DFG-in to DFG-out), as previously proved for Abl (Chap-
ter 3). However, when this condition is not satisfied, as for Met and EGFR (flexible
N-lobe only), the imatinib activity results compromised. From this analysis, was con-
firmed the relation existing between sub-µs dynamics, conformational dynamics and
imatinib activity in TKs.
TK A-loop RMSF (Å) IC50 (µM)
Abl 4.2 0.037 [62]
Kit 5.5 0.3 [63]
Lck 3.2 9 [56]
Met 2.6 >100 [64, 65]
EGFR 2.5 >100 [66]
Src 2 >100 [66, 65]
Table 4.1: RMSF of the A-loop region and IC50 values of imatinib reported in literature for
Abl, Src and the homologous TKs[93].
4.4 Principal component analysis
All tyrosine kinases are characterised by dominant motions involving the N-lobe and
the C-lobe of the kinase domain. Two main motions have been described[70, 41]: the
hinge-bending motion, where N-lobe and C-lobe get closer (see Figure 4.4, image a),
and the lobe twist of the N-lobe relative to the C-lobe (see Figure 4.4, image b).
Figure 4.4: Schematic representation of the KD dominant motions: the hinge-bending motion
(a) and the lobe twist (b). Both are characterised by movements of the N-lobe relative to the
C-lobe.
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To investigate if the change in the sub-µs dynamics could also affect the kinase
dominant motions, a PCA analysis of the TKs trajectories was performed. The first two
eigenvectors contributing most significantly to the enzyme dynamics were chosen. As
discussed in Section 2.1.5, the trajectories of all homologous TKs were projected on
Abl first and second eigenvectors. This allowed to compare the conformational space
visited by every kinase with respect to Abl (chosen as reference of a flexible kinase in
the study). The first eigenvector describes the movement of the N-lobe (hinge motion),
while the second eigenvector describes mainly the lobe twist (see Figure 4.4).
Figure 4.5: PCA analysis. Comparison of the conformational space explored by the homolo-
gous TKs under study (Src, Kit, Lck, Met and EGFR) with respect to Abl. The first eigenvector
(Abl eig 1) describes the hinge motion, while the second eigenvector (Abl eig 2) the lobe twist.
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All the TKs under investigation explore a smaller subspace compared to Abl (see
Figure 4.5). Moreover, most TKs (Kit, Lck and Met) visit a different portion of the con-
formational space, in particular considering the first eigenvector, which corresponds to
the hinge motion (see Figure 4.5). The projections of Src and EGFR, instead, partially
overlap with the one of Abl (see Figure 4.5).
As expected, TKs share a common dynamics due to their KD structure, but they
have in addition a unique dynamic pattern determined by their own sequence. The
plasticity shown by Abl is particularly high, and it spans a great number of different
conformations. For example, the N-lobe and the αC-helix of Abl have a peculiar be-
haviour, previously described in Chapter 3, not observed in the homologous TKs thus,
becoming a distinctive feature of Abl.
4.5 Experimental validation
On the whole, the results on the homologous TKs of Src and Abl show a link between
the A-loop flexibility and the activity of imatinib: the kinases with the most flexible A-
loop are the ones reporting the lower IC50 values. However, other structural elements,
such as the N-lobe loops, might also play a role in the drug binding.
In the Introduction (see Section 1.5.2) I discussed the differences in the binding
modes of two classes of kinase inhibitors: type I and type II[115, 108]. Type I inhibitors
occupy just the ATP binding site, docking below the P-loop (refer to Figure 1.20 of the
Introduction). Type II, as imatinib, occupy both the ATP binding site and the allosteric
pocket (refer to Figure 1.20). In the light of this, the high flexibility of the P-loop region
of Met and EGFR shown in the RMSF analysis gains importance[115, 108].
In this section, the experimental results in Ref [213] were used to cross-validate
the model of kinase dynamics proposed in this thesis, against a broader range of TK
inhibitors. The aim was to better understand the correlation existing between the sub-
µs dynamics of the N-lobe and A-loop regions and the binding of drugs.
Peterson and coworkers[213] carried out a remarkable wide-scale study on the cat-
alytic activity of various kinases against commercially available inhibitors. The results
of this analysis are reported in Figure 4.6. Remarkably, the ’activity matrix’ across
the six selected kinases for the subset of compounds clustered itself in three different
blocks, covering around the 70% of the analysed data. The first block is characterised
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by a high activity towards four kinases (Abl, Kit, Lck and Src) and comprises type I
inhibitors, as dasatinib and sunitinib. The second block differs from the first one for the
lack of activity towards Src, while retaining the effect against Abl, Kit and Lck. This
block comprises imatinib itself and other compounds as nilotinib and masitinib (type
II inhibitors). A third block is observed, with a strikingly different pattern, composed
mainly of drugs active against EGFR only. Not surprisingly, the well known highly spe-
cific EGFR inhibitors erlotinib and gefitinib were found in this category. The remaining
compounds, not belonging to any group in particular, were identified as either highly
selective towards one kinase (e.g. Src and Met inhibitors) or as nonspecific inhibitors,
like staurosporine.
When compared to the flexibility pattern of the A-loop and of the N-lobe, signifi-
cant analogies could be observed. The first block of compounds presents a separation
across the pool of kinases similar to the one observed for the N-lobe RMSF. Abl, Kit,
Lck and Src with lower N-lobe fluctuations have also a lower residual catalytic activity,
so that are effectively inhibited when treated with compounds of this group (type I).
Conversely, the second group (type II) has a trend which is opposite to the flexibility
observed for the A-loop. Abl, Kit and Lck with a more flexible A-loop have a lower
residual activity.
Therefore, it seems that a low P-loop flexibility is needed, probably to assure a
better stability to the binding of type I inhibitors. As evidence of this, type I inhibitors
are not effective in kinases showing an excessive P-loop flexibility, as Met and EGFR.
On the contrary, the high flexibility of the A-loop region seems to be crucial for the
activity of type II inhibitors, since all kinases having a rigid A-loop are not inhibited by
imatinib or any other type II binder.
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Figure 4.6: The activity matrix shows the residual catalytic activity for each kinase-drug match
retrieved from the results obtained in the work of Ref. [213]. Shades of green identify the
kinases effectively inhibited by the considered drug, so having a low residual catalytic activity,
while shades of red identify kinases not inhibited by the drug and maintaining an high residual
activity. With residual activity is meant the ability of the kinase to phosphorylate biological
substrates. The drugs tested in the study have been grouped according to their binding mode
to the kinase (type I, type II). To the other groups belong the EGFR specific inhibitors and the
nonspecific inhibitors).
4.6 Discussion
Tyrosine kinases, even those with a significant sequence identity, show a wide range
of sensitivity towards inhibitors that cannot be easily explained considering only their
sequence or the 3D structure. The results presented in this Chapter show that sub-µs
dynamics is able to discriminate among kinases, even when their sequence is more
than 45% identical, thus becoming crucial as a descriptor of the kinase behaviour, as a
kinase ’fingerprint’. Every TK turns out to have a peculiar sub-µs dynamics, that could
be related to the inhibitor’s selectivity.
The engagement and final binding of a drug to a target is a complex process, that
involves many steps and conformational changes in both the target and the drug. Know-
ing the structural and also the dynamical specificities of a target is therefore essential
for the design of effective drugs. Nowadays, the view of the binding event has evolved
from the "lock and key" theory[4]. The targets are considered as dynamic entities and
more emphasis is given to the study of their intrinsic dynamics and conformational
landscape[3, 9, 10].
In this Chapter a clear trend was identified, proving that the dynamics of specific
regions in the TK structure are more involved than others in the binding process of
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drugs. For example, the dynamics of the P-loop and the A-loop is strictly correlated
with the activity of inhibitors, because both involved in the conformational changes
that lead to the adoption of the druggable conformations (DFG-in for type I inhibitors,
DFG-out for type II).
Chapter 5
Src mutagenesis confirms the link
between flexibility and imatinib
binding affinity
Based on the computational evidence discussed in Chapters 3 and 4, the flexibility of
specific regions within the kinase domain seems to be connected to imatinib activity in
TKs. To further validate these results, a number of mutants were engineered in order to
increase the sub-µs dynamics of the Src KD.
In this Chapter, I will describe the mutagenesis study undergone to understand
whether inducing a change in the kinase dynamics is sufficient per-se to increase the
sensitivity towards imatinib. In the first part of the mutagenesis study, MD simulations
of the engineered mutants of Src were performed in order to predict their flexibility.
Subsequently, those showing a significant increase in flexibility in silico were chosen
for the second, experimental, part of the study. The selected mutants were expressed
in E.coli cells, then purified and finally the binding affinity (Kd) of imatinib was deter-
mined by means of isothermal titration calorimetry (ITC).
The identification of mutants able to alter the sub-µs dynamics of Src, as well as
their expression and purification, required a lengthy trial and error procedure.
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5.1 Selection of the Src mutants included in the study
The amino-acid sequence of Abl and Lck, both flexible and imatinib sensitive kinases,
were taken as references. Since Lck shares the highest sequence identity with Src (70
%), it was used as template, reducing the number of residues to mutate.
The mutations were designed in order to increase the structural flexibility of Src,
following two main strategies. On the one hand, mutating regions with a major vari-
ation in dynamics among the homologous TKs, on the other hand, breaking contacts
responsible for structural stabilisation.
The mutations aimed to modify Src flexibility were engineered in the P-loop, β3-
αC loop, A-loop and αG-helix (see Figure 5.1). In these regions, the residues of Src,
that differ among the three kinases, were mutated into the corresponding residues of
Lck and Abl (to obtain a progressive increase in flexibility). The selected residues
were: Q275 (P-loop), P299 (β3-αC loop), Q420 (A-loop) and V461 (αG-helix). To
note is that the mutation of the αG-helix was meant to rigidify this region (and not to
make it more flexible), in order to mimic Abl behaviour.
Since this approach was not fully successful, other mutants were designed (see
Figure 5.1), this time aimed to break crucial contacts within the Src structure: E415G
(A-loop), Y416G (A-loop) and M302G (αC-helix). Single and triple mutants of Src
were designed.
5.2 MD simulations and RMSF analysis of the
engineered mutants of Src
To test the flexibility of the Src mutants and determine the impact that mutations have
on the sub-µs dynamics, preliminary MD simulations were performed (for details see
Section 2.1.4). Four single mutants were initially tested (see Figure 5.1): Q275A,
P299Q, Q420E and V461I (Src to Lck mutations).
In general, every engineered mutant perturbs the dynamics of regions far away
from the mutated site. This confirms the presence of an extensive allosteric network of
coupled residues spanning the kinase domain, as also mentioned in Ref [17].
As shown in Figure 5.2, the regions most affected by the mutations are: the P-loop,
the αG-helix and the αD-helix. The mutations (see Figure 5.1) increase the flexibility
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Figure 5.1: Structure of the kinase KD with highlighted the positions of the engineered mutants
of Src. The mutations affecting Src dynamics are coloured in orange, the ones affecting Src
contacts are coloured in cyan.
of the P-loop and decrease the ones of the αG-helix. The only exception is P299Q (β3-
αC loop mutant), in which the αG-helix becomes more flexible than in the wild-type
(3.8 Å, Figure 5.2).
The mutagenesis analysis shed the light on the strong allosteric correlation be-
tween the P-loop and the αG-helix, not previously detected (allosteric coupling analy-
sis, Section 4.2). A clear example of this connection is the αG-helix mutant (V461I), in
which the P-loop is the only region affected by the mutation (see Figure 5.2). Finally,
the behaviour shown by the αD-helix is unusual, and not further observed in the RMSF
analyses performed on the triple mutants of Src engineered later on.
As just mentioned, since the increase in the sub-µs dynamics of Src WT obtained
by single mutations was minimal, triple mutants were attempted. The triple mutants
tested were Q275A/P299Q/Q420E (mutations Src to Lck) and Q275G/P299E/Q420A
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(Src to Abl). The mutated areas were the P-loop, the β3-αC loop and the A-loop (see
Figure 5.1).
Taking the RMSF profiles of Src, Lck and Abl as references for a rigid, in-
termediate and highly flexible KD, the triple mutants are predicted, by the simula-
tions, to mostly affect the flexibility of the N-lobe (see Figure 5.3 and Figure 5.4).
Q275A/P299Q/Q420E reaches the 2 Å flexibility in the P-loop and in the β2-β3 loop.
Unfortunately, the flexibility of the A-loop region seems to be unaffected by the se-
lected mutations (see Figure 5.3), while the αG-helix shows a decreased flexibility of
about 1 Å, as in Abl (see Figure 5.4). A similar flexibility pattern is predicted for the
Q275G/P299E/Q420A mutant. As expected, the average intensity of the fluctuations
is higher and in some regions, as the P-loop and the αC-helix, exceeds the values pre-
dicted for Abl (see Figure 5.3). A slight increase in flexibility results for the A-loop.
However, even a triple mutation seems not to be sufficient to affect dramatically the
dynamics of the A-loop. This might be due to the allosteric regulation acting on this
functionally relevant motif.
To test this hypothesis, I also tried to affect the flexibility of the A-loop indirectly
by mutating the αC and αG helices, supposed to be allosterically connected to the A-
loop[17]. The new triple mutants (see Figure 5.1) created were Q275A/P299Q/Q309A
(Q309A, mutation on the αC-helix Src to Lck) and Q275G/P299E/V461S (V461S,
mutation on the αG-helix Src to Abl). Unfortunately, no appreciable change in the
flexibility was noticed for the first mutant, probably due to the very high sequence
variability of the αC-helix region throughout kinases, making difficult obtaining an
effect only with a single point mutation. Better results were obtained with the αG-helix
mutant (see Figure 5.3), where the P-loop and the αG-helix itself were flexibilised and
rigidified respectively, resembling the Abl behaviour (average RMSF of 1 Å in the αG-
helix, see Figure 5.4). However, again no effect on the A-loop flexibility was observed.
The absence of any substantial change in the αC-helix and A-loop regions was
surprising, even more considering that in the case of the Q275A/P299Q/Q420E mu-
tant, Q420 is the only residue that differs between the A-loop of Lck and Src. A further
attempt was the substitution of the entire αC-helix of Src with the one of Abl. Un-
expectedly, the chimera generated by mutating 14 residues determined the complete
suppression of the sub-µs dynamics, not only of the αC-helix but of the Src structure
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Figure 5.3: (a) RMSF profiles of Src (blue) and Abl (red). Grey panels identify the N-lobe
and the A-loop region. (b) RMSF profiles of the engineered mutants of Src. In the two panels
are reported the RMSF profiles of the N-lobe region (left) and A-loop region (right). Shades of
red identify the more flexible mutants, shades of blue the more rigid. Dotted lines are used for
clarity. Figure taken from Ref [93].
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Figure 5.4: RMSF profile of the αG-helix of Src, Abl and the engineered mutants of Src.
Shades of red identify the more flexible mutants, shades of blue the more rigid. Dotted lines are
used for clarity. Figure taken from Ref [93].
in general, as shown in Figure 5.3 and 5.4.
In the attempt to flexibilise the A-loop, new mutations were designed in such a
way to disrupt crucial contacts within the Src structure, focusing on those stabilising
the αC-helix and the A-loop (see Figure 5.1).
Crystal structures of Src show the A-loop forming a helix turn, supposed to sta-
bilise the loop in an open active-like conformation. The same behaviour was also re-
ported in computational studies of EGFR[100, 214] and FGFR[103]. Therefore, mu-
tations E415G and Y416G, disrupting the helix turn, were attempted (see Figure 5.1).
Single and double mutants (E415G/Y416G) were tested for flexibility in silico, also
a triple mutant bearing these two mutations together with the one on the αG-helix
(V461S, see Figure 5.1). Again, a weak change in flexibility was achieved but only in
the A-loop of the triple mutant (see Figure 5.5).
Subsequently, to increase the flexibility, this time of the αC-helix, a glycine was
introduced (M302G, see Figure 5.1) to create a flexible point in between the helix and
the preceding loop (β3-αC loop). The M302G mutant determines change in the overall
Src dynamics very similar to the Q275G/P299E/Q420A mutant (Src to Abl), with the
exception of the αG-helix region, not rigidified (see Figure 5.5).
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Figure 5.5: RMSF of the engineered mutants of Src: M302G and E415G/Y416G/V461S. The
RMSF profile of the mutant (cyan dotted line) plotted with the two references profiles of Abl
(red line, flexible) and Src WT (blue line, rigid). The dots in cyan identify the sites of the
mutation and the bars the regions of the structure whose fluctuation results affected by the
mutation.
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5.3 Expression and purification of the engineered
mutants of Src
The triple mutants, showing major differences in the sub-µs dynamics predicted in
silico, were tested for imatinib affinity. The final candidates for expression and purifi-
cation were: Q275A/P299Q/Q420E (Src to Lck), Q275G/P299E/Q420A (Src to Abl),
Q275A/P299Q/V461S (Src to Abl, with mutation of the αG-helix) and finally the αC-
chimera as a counterexample, given the suppressed dynamics. The mutants were ex-
pressed in E. coli cells, purified and their affinity towards imatinib tested by means of
isothermal titration calorimetry (ITC) experiments.
The expression of the triple mutants and of the Src chimera resulted in a very
extensive molecular biology study. The introduction of up to three mutations in the
Src structure was sufficient to change completely the protein behaviour. In fact, it was
impossible to express the mutants following the same protocol successfully used for
the expression of Src WT. It followed the need to design an alternative protocol for
the expression and also the purification of the mutants (for details see Section 2.2.3).
In Figure 5.6 are shown the chromatograms of the two purification steps performed
(affinity chromatography (image a) and size-exclusion chromatography (image b)). In
image c, Figure 5.6, there are the gels showing the mutants obtained at the end of the
purification process.
5.4 ITC experiments of the engineered mutants of Src
The experimentally measured Kd (see Figure 5.7) appears to correlate well with the
RMSF values registered for the mutants (see Table 5.1, lower the Kd higher the affin-
ity of imatinib for the mutant). It progressively decreases as the A-loop fluctuations
increase and when the αG-helix is stabilised, as in mutant Q275G/P299E/V461S (see
Figure 5.3 and 5.4). At the same time, the Kd of imatinib for the αC-helix chimera
increases to14 µM (Src WT=12 µM), thus constituting a cross-validation for which a
lower imatinib affinity is associated with the loss of sub-µs dynamics in the kinase.
Albeit, all Src mutants registered a decreased Kd (thus a higher sensitivity to ima-
tinib), the change in the binding affinity of the drug was smaller than what one would
have expected, assuming that the sub-µs dynamics in itself plays a major role in the
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Figure 5.6: (a) HisTrap column chromatogram: the protein of interest is the more intense UV
signal. (b) size-exclusion S75 column chromatogram: the protein of interest corresponds to the
last signal. (c) Gels identifying the obtained mutants of Src after purification (around 35 kDa).
Figure taken from Ref [93].
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Figure 5.7: ITC curves resulting from the experiments performed and reporting the imatinib
binding curves towards Src WT and the engineered mutants of Src. Figure taken from Ref [93].
Protein A-loop RMSF (Å) Kd (µM)
Abl WT 4.2 0.08 [20]
Q275G/P299E/V461S 1.4 6.2
Q275G/P299E/Q420A 2.5 7.3
Q275A/P299Q/Q420E 1.8 8.5
Src WT 2 12
αC chimera 0.3 14
Table 5.1: RMSF values of the A-loop region, averaged from MD calculations, and the re-
trieved Kd for Src WT and the engineered mutants of Src by means of ITC (data published in
Ref [93]). Lower the Kd , higher the affinity of imatinib for the kinase. The Kd value of Abl was
recovered from the work of Seeliger et al.[20].
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binding. However, in contrast with previous studies in which similar Kd values were
obtained[20] (see Figure 5.8), it is important to notice that all the mutated residues in
the work presented in this thesis were chosen far from the binding site and not engaging
in direct interactions with the drug.
Figure 5.8: Figure taken from Ref [20]. ITC curves of imatinib binding to Abl (A) and Src (B).
In (C) Kd values of imatinib obtained for Abl WT, Abl phosphorylated and Abl L384G mutant.
In (D) Kd values of imatinib binding to Src WT and to some of the Src mutants described in the
Ref [20]. Noticeable is the choice of the mutated residues, all in the immediate vicinity of the
DFG motif (Asp404-Phe405)[20].
It is particularly interesting Q275A/P299Q/V461S, the αG-helix mutant, register-
ing the highest affinity for imatinib. The RMSF shows a rigidification of the αG-helix,
mimicking Abl WT, but not the flexibilisation of the A-loop. From the analysis of the
MD trajectories, the αG-helix of Src WT was seen to adopt two main conformations,
shown in Figure 5.9. On the contrary, the αG-helix of the mutant only adopts one
(image A, in Figure 5.9), in which the helix is interacting with the A-loop stabilising
both regions. Thus, the connection existing between these two regions in Src is not
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allosteric, as thought at the beginning, but mainly due to formation and breakage of
contacts. The rigidification of the αG-helix achieved in mutant Q275A/P299Q/V461S
(mimicking Abl) is also responsible for the undesired stabilisation of the A-loop.
A B
A-loop
G-helix
A-loop
G-helix
Figure 5.9: αG-helix conformations (A, B) sampled in the trajectory of Src WT. Figure taken
from Ref [93].
5.5 Discussion
Based on the computational results, I performed a rational mutagenesis of the Src KD
to make more flexible the rigid motifs (P-loop, β3-αC loop, αC-helix, A-loop) and
vice-versa (αG-helix). The engineered mutants affect the sub-µs dynamics of the Src
KD and, consequently, also imatinib Kd . This was a further evidence of a connection
between sub-µs dynamics and imatinib affinity in TKs.
Furthermore, the mutagenesis study performed shed light on the complex al-
losteric network of Src summarised in Figure 5.10. It confirms the essential role of
the αC-helix in the regulation of the KD, indeed its substitution in the chimera mutant
determines a complete suppression of the dynamics. Also, the αG-helix and the P-loop
regions (see Figure 5.10) show not only a strong cross-correlation between themselves,
but also a high degree of connection to the overall kinase network, because always per-
turbed by other mutations. In particular, the αG-helix gains importance as strategic
area in the overall KD regulation of Src, for the interactions it makes with the A-loop.
However, the flexibilisation of the A-loop was unsatisfactory for all mutants tested,
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Figure 5.10: Structure highlighting the location of the engineered mutants of Src. The muta-
tions affecting Src dynamics are coloured in orange, the ones affecting Src contacts and struc-
ture are coloured in cyan. Arrows are illustrating the major allosteric pathways identified by
the mutagenesis study, coloured accordingly to mutant. The connection between P-loop and
αG-helix is a feature of the Src structure.
and the subsequent change in the binding affinity of imatinib smaller than expected.
The impossibility to effectively modify the dynamics of crucial areas involved in the
conformational changes of Src, as the A-loop and in a lesser extend the αC-helix,
could be explained considering a much more complex allosteric mechanism regulating
the dynamics of these two regions[17, 41, 15]. For example, in a recent paper from
Dölker and co-workers, a significant allosteric effect of the SH2 subunit acting on the
αC-helix of Abl (refer to Figure 1.9 of the Introduction) was shown[41]. Similarly, in
Src other subunits (SH2 and SH3) could be involved in the regulation of the KD.
What is clear is the presence of a complex interplay between allostery, sub-µs
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dynamics and large conformational changes. In agreement with these considerations, it
was also proposed in other works the presence of several concurring distributed factors,
after that other extensive mutagenesis in Src and Abl failed to identify a single amino-
acid responsible for the difference in imatinib activity[20]. However, the observation
that sub-µs fluctuations are able to discriminate among kinases sensitive to imatinib
might be used to predict the effect of selected mutations in cancer samples.
Chapter 6
Understanding of the molecular
mechanism of imatinib resistance
In the previous chapters I reported evidence from computations and experiments show-
ing that sub-µs dynamics is able to discriminate among different kinases, even when
the sequences have more than 45% sequence identity. A special correlation was iden-
tified between the dynamics of regions involved in the conformational changes of the
kinase and the activity of TKs inhibitors. The engineered mutants of Src shown that a
gain in flexibility, even a small one, could enhance the affinity of imatinib to a kinase
such as Src, which normally binds to imatinib with a very low affinity.
In this chapter, I will investigate the mechanisms of drug resistance in Abl. Most
resistant mutants of Abl are extremely effective in impairing imatinib activity, even if
they only harbour single point mutations. A well studied example is the "gatekeeper"
mutant T315I[87, 94, 1], which was initially thought to block the binding due to a
steric clash. Indeed, as many mutations are localised in the KD close to the catalytic
pocket [88, 89], they could directly affect the binding. However, the mechanism of
action of most mutations is still unknown as they are far from the binding site.
An exhaustive analysis was conducted by means of classical MD simulations and
enhanced-sampling PTmetaD calculations, to investigate the dynamics of several resis-
tant mutants of Abl. In agreement with the results reported in the previous chapters, the
mutants analysed modify both the sub-µs dynamics and large conformational changes
of the kinase, confirming once more the importance of dynamics in imatinib activity.
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6.1 Selection of the Abl resistant mutants included in
the study
To assess in detail how the dynamics is affected when resistance-inducing mutations
arise in the kinase, four mutants of Abl were selected. The candidates were chosen
among the clinical mutations found in chronic myeloid leukemia patients and collected
in the works of Azam et al.[88, 89], having an unknown mechanism of resistance and
a big impact on the IC50 of imatinib. The final mutants were: G250E, a single point
A
B
Figure 6.1: (A) IC50 values of imatinib corresponding to the resistant mutants of Abl collected
in the work of Azam et al.[88], compared to the IC50 of Abl (in red). The mutations are divided
in those lying in flexible regions of the Abl KD (in orange) and those lying in more constrained
areas (in green), also directly highlighted on the Abl structure (B). As it could be noticed the
mutations on flexible regions (P-loop, A-loop, αC-helix, αG-helix) have a more drastic impact
on the IC50 (higher is the value, lower is the inhibitory effect of imatinib towards Abl).
mutation located on the P-loop (IC50 = 20 µM), E279K, mutant of the β3-αC loop
(IC50 = 9.9 µM), H396P, mutant of the A-loop (IC50 = 9 µM) and E450K, mutant of
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the αG-helix (IC50 = 2.3 µM).
Investigating the pathological mutations of Abl[88], it was noticed that the ones
that mostly affect the IC50 of the drug, were prevalently located in regions of the struc-
ture recognised as flexible in the previously performed RMSF analyses (see Chapters
4, 5 and Figure 6.1). Being mutational hotspots, is per se a proof of the functional role
played by flexible regions with regards to imatinib activity.
For completeness, the "gatekeeper" mutant of Abl, T315I (IC50 > 20 µM)[88]
was added to the pool of mutants under study. Diverse mechanisms of action have
been proposed for this mutant: a "direct" one, with the elimination of an hydrogen
bond crucial for the high-affinity binding of imatinib[91, 61], or to impede the in-
duced fit mechanism proposed for Abl[79, 80], determined by the adoption of a kinked
conformation of the P-loop, or even the modulation of the activation mechanism via
conformational selection, as shown for others "gatekeeper" mutants in homologous
kinases[100, 101, 102, 103].
6.2 Classical MD simulations and RMSF analysis of
the resistant mutants of Abl
MD simulations and RMSF analyses were performed for all the resistant mutants of Abl
(for details see section 2.1.4). The results show a considerable change in the flexibility,
with a clear tendency of all resistant mutants to adopt a more rigid "Src-like" profile.
On average, the difference in RMSF between Abl WT and the mutants is of about 1.5
Å (see Figure 6.2). The main regions to be affected are again the N-lobe, the A-loop,
and, to a lesser extent, the αG-helix.
In the G250E mutant, the N-lobe loops are largely affected (P-loop, β2-β3 loop
and β3-αC loop) together with the A-loop, with a RMSF decrease of about 1 Å and al-
most 3 Å, respectively. The E279K and H396P mutants show similar RMSF profiles. In
both cases, there is an important decrease in flexibility with respect to the WT in the β3-
αC loop and, particularly, in the A-loop (of about 2 Å). The allosteric communication,
between the β3-αC loop and the A-loop in Abl, results in both loops being affected
even when only one of the two bears the mutation. The β3-αC loop is known to play
a role in the activation of Abl, via allosteric regulation by the SH2 domain[41, 213],
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Figure 6.2: (a) RMSF profiles of Src (blue) and Abl (red). Grey panels identify the N-lobe and
the A-loop with αG-helix region. (b) RMSF profiles of the resistant mutants of Abl. In the two
panels are reported the RMSF profiles of the N-lobe region (left) and A-loop with αG-helix
region (right), being the areas whose flexibility varies most among the pool of TKs. Shades of
red identify the flexible mutants, shades of blue the more rigid ones. Dotted lines have been
used for clarity. Figure taken from Ref [93].
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so its connection with the A-loop becomes even more relevant. A small but significant
increase in RMSF can also be observed for the αG-helix, especially in the E279K mu-
tant. Only minor changes, were instead registered for the αG-helix mutation (E450K),
where the only affected region is the β3-αC loop.
Apparently, the decrease in flexibility, especially in the N-lobe and A-loop regions,
although far from the binding site, is reflected in a loss of imatinib activity, in line with
what was observed for the pool of homologous TKs, previously discussed (see Section
4.3).
6.3 Principal component analysis
To investigate if the Abl dominant motions were also affected by the mutations, PCA
analysis was performed for the resistant mutants of Abl. As previously described in
Section 4.4, the first two eigenvectors of Abl wild-type (WT) were used. The first
eigenvector describes the movement of the N-lobe (hinge motion), while the second
eigenvector describes mainly the lobe twist (refer to Figure 4.4 of Chapter 4).
A change can be appreciate in particular for G250E, the P-loop mutant, in the
subspace it explores (see Figure 6.3). Most affected are the movements of the N-lobe,
represented by the first eigenvector, which are drastically reduced and shifted towards
a different region of the conformational space compared to the wild-type. The A-loop
movement, corresponding to the second eigenvector, shows a more restricted ensemble
of conformations. For E279K, H396P and E450K, the space explored overlaps with
the one of Abl WT, although reduced along both directions. For the gatekeeper mutant,
T315I, the space explored is substantially reduced along eigenvector 1 while, almost
identical to the WT along eigenvector 2.
On the whole, the analyses of the sub-µs dynamics show a connection between
the A-loop fluctuations and imatinib activity. Not only homologous TKs with lower
RMSF seem to be less sensitive to imatinib (see Chapter 4), but also the pathological
drug-resistant mutations of Abl induce a similar shift in the sub-µs dynamics.
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Figure 6.3: PCA analysis. Comparison of the conformational space explored by the resistant
mutants of Abl with respect to Abl WT.
6.4 PTmetaD-WTE calculation and free-energy
surface reconstruction
The observed changes in the sub-µs dynamics may probably be a proxy for a more
global entropic impediment of the inactive DFG-out conformation itself, or in other
words, a shift towards the kinase active conformation. Recently, it was demonstrated
that over-activation of kinases, in the presence of oncogenic mutants, is indeed con-
nected with a population shift towards the active DFG-in conformation, accompanied
by some degrees of rigidification[100, 101, 102, 103].
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To further investigate how the conformational landscape of Abl WT changes due
to mutations, massive multiple-replica PT-MetaD simulations were performed to com-
pute fully converged conformational free energy landscapes (for details see Section
2.1.6 and Figures 6.5 and 6.6), associated with the four drug-resistant mutants (G250E,
E279K, H396P, E450K) and the "gatekeeper" mutant T315I (see final FESs in Figure
6.4). The same set of CVs used in the PTmetaD simulations of Src and Abl WT (see
Chapter 3) were considered. As expected, for all the mutants the global minimum of
the FES corresponds to the DFG-in conformation (see Figure 6.4). The FESs also ex-
hibit a second minimum corresponding to the DFG-out, much more pronounced in the
case of G250E and T315I, while not always well-defined in the others (e.g. E279K and
E450K).
All resistant mutants show a significantly altered landscape, in particular H396P,
E279K and E450K, remarkably similar to the one of Src. The G250E and T315I mu-
tants, show a ∆G and a barrier very closed to Abl WT(4.0 ± 0.5 kcal/mol and barrier
6.0 ± 0.5 kcal/mol). However, the disappearance of the third local minimum, present
in Abl WT surface and corresponding to the intermediate Asp-down conformation,
confirms clearly that the DFG flip mechanism has been significantly altered by the
mutations. The DFG-in minimum, in T315I, is particularly broad and much more pop-
ulated than the DFG-out. While, the DFG-out conformation of G250E has a peculiar
and never reported "out-out" conformation, adopted by both Asp404 and Phe405 (see
Figure 6.7). The A-loop reaches the fully open conformation, accompanied by a loss
of structural integrity in both the αC and αG helices (see Figure 6.7). Even if ener-
getically the DFG-out does not seem to be affected, structurally the unfolding events
and the inappropriate DFG-out conformation could account for changes in the binding
mechanism of imatinib. The same out-out position of Asp404 and Phe405 has been
observed also in the mutant E450K (Figure 6.7), that has a less stable DFG-out confor-
mation, ∆G of 6.0 ± 0.5 kcal/mol, but an energy barrier for the DFG flip equal to Abl
WT (around 6.0 ± 0.5 kcal/mol).
In the other two mutants, H396P and E279K, the DFG flip results to be even more
strongly hindered with a ∆G of 7.0± 0.5 kcal/mol and 8.0± 0.5 kcal/mol, respectively,
and an energy barrier of 9.0 ± 0.5 kcal/mol closer to the one registered for Src (11.0 ±
0.5 kcal/mol). Thus, not only the energy barrier is increased but the DFG-out minimum
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Figure 6.5: 2D projections showing the convergence of the free-energy of the resistant mutants
of Abl (E450K,H396P and E279K). The error on the minima and barriers of the FESs amounts
to 0.5 kcal/mol. Figure taken from Ref [93].
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Figure 6.6: 2D projections showing the convergence of the free-energy of the resistant mutants
of Abl (G250E and T315I). The error on the minima and barriers of the FESs amounts to 0.5
kcal/mol. Figure taken from Ref [93].
is less stable than in Src (6.0 ± 0.5 kcal/mol). For the E279K and E450K mutants, the
DFG-out conformation is not even an energy minimum at all. Instead, the Asp-down
conformation seems to be more stable and to be a secondary minimum for E279K and,
in a lesser extend also for E450K. The DFG-out conformation in H396P is characterised
by the complete unfolding of the αC and αG helices (see Figure 6.7). The loss of
integrity of these two structural elements, critical for kinase functionality, could be a
consequence of the higher rigidity of the structure, leading to the A-loop not being
able to rearrange properly in the flipped conformation. Moreover, the A-loop in the
DFG-out conformations of all mutants tends to be more helical, forming a second helix
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turn, characteristic of the open A-loop of Src WT[214, 215, 103] (see Figure 6.8). The
residues involved in the helix turn, from Asp391 to Ala395 (Abl 2G1T.pdb numbering),
in the case of H396P are situated right before the mutation.
Figure 6.7: DFG out-out conformation identified in the DFG-out minima of G250E (a) and
E450K (b). Unfolding of the αC and αG helices in G250E (c), E279K (d), H396P (e, f) and
E450K (g). Figure taken from Ref [93].
Figure 6.8: Structures of Src WT (a), G250E (b), E279K (c), H396P (d), E450K (e) and
T315I (f) showing the formation of a helix turn in the A-loop of the resistant mutants of Abl,
resembling Src. In sticks is shown the DFG motif and in H396P mutant in red the site of the
mutation, located exactly after the helix turn. Figure taken from Ref [93].
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Remarkably, all resistant mutants explore a reduced conformational landscape
than Abl WT along both CVs, as observed for Src. In particular they never explore
CV2 values above 1.7 nm. An effect which appears to be more significant in the case
of the DFG-out conformation and may explain why the RMSF profiles are predictive
of the drug activity.
6.5 Estimating the entropic and enthalpic contribution
to the ∆Gin−out
The entropic and enthalpic contribution to ∆Gin−out in function of the temperature were
estimated from the replicas of the PTmetaD simulations of Src, Abl WT and the resis-
tant mutants. Figure 6.9 shows the linear regressions obtained for each simulation and
in Table 6.1 are collected the corresponding entropic and enthalpic contributions re-
trieved.
Figure 6.9: Linear regressions of Abl WT, Src and the resistant mutants of Abl. Each point of
the regression corresponds to the ∆Gin−out calculated for each replica of the system at different
temperature. This was repeated for the PTmetaD simulations performed. Figure taken from Ref
[93].
The destabilisation of the kinase inactive DFG-out conformation for some of the
resistant mutants is due to an entropic loss in the passage from DFG-in to DFG-out (see
Table 6.1). The only exceptions are G250E and T315I mutants, for which the transi-
tion results to be entropically favoured (Table 6.1). Thus, classical MD simulations of
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the DFG-out conformation of Abl WT, Src and the resistant mutants were performed
(see details in Section 2.1.4) to check for the sub-µs dynamics also of the druggable
conformation. Effectively, the RMSF analysis performed confirms that just for G250E
and T315I, the DFG-out conformation experiences a slight increase in the fluctuations
of the A-loop (see Figure 6.10).
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Figure 6.10: RMSF profiles of the DFG-in (in orange) and DFG-out (in green) conformations
for Abl WT, Src and the reisstant mutants of Abl. Figure taken from Ref [93]
The destabilisation of the kinase inactive conformation caused by some ima-
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tinib resistant mutants is in striking agreement with the published works on oncogenic
mutants[98, 100], confirming that the destabilisation of the DFG-out drives a shift to-
wards the DFG-in in both oncogenic and imatinib resistant mutations.
TK ∆H (kcal/mol) T∆S (kcal/mol)
Abl -3.56 -8.01
E450K -2.66 -8.96
T315I 17.93 13.06
H396P -7.61 -14.51
E279K 1.02 -6.90
G250E 43.69 39.79
Src -9.73 -15.28
Table 6.1: Entropic and enthalpic contributions to the ∆Gin−out in Abl WT, Src and all the
resistant mutants of Abl. The values have been obtained from the linear regressions of the
∆Gin−out as a function of temperature shown in Figure 6.9 with equation ∆G=∆H-T∆S. Figure
taken from Ref [93].
6.6 Free energy reweighting
Still difficult to characterise is the role played by the mutations in G250E and T315I
mutants. In literature it is mentioned that oncogenic mutants are able to cause hyper-
activation of the kinase, as confirmed by a common mechanism of resistance that con-
sists in locking the kinase in its biologically active conformation, ready to bind ATP and
to phosphorylate substrates[102, 103]. Similarly, the previous calculations suggest that
imatinib resistant mutations could not only destabilise the druggable, DFG-out confor-
mation of Abl WT thus impairing imatinib binding, but probably also shift the A-loop
towards more open ’active like’ structures. It has been shown that the "active-like"
conformation of TKs, with the A-loop open but not phosphorylated, is just marginally
stable and can be stabilised by ATP binding[73, 100, 75].
To further investigate this aspect, I analysed how the mutations alter the open-
closed equilibrium of the A-loop. The reweighting of the PTmetaD simulations was
performed (see Section 2.1.8) in order to include two additional collective variables,
able to describe the opening of the A-loop (see Figure 6.11).
In agreement with recent calculations on Src WT[73], the open conformation of
the A-loop in both Abl and Src WT (CV1<6) are highly disfavoured (see Figure 6.11).
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Nonetheless, a striking difference can be observed in the FESs of the resistant mutants.
If for Abl WT and Src the deepest minima correspond to the semi-open or closed con-
formation of the A-loop (see Figure 6.11, B or C respectively), all mutants show a major
variability and a more complex landscape, with multiple metastable minima and A-loop
"open like" conformations partially stabilised. Furthermore, in G250E, E450K and to
a lesser extend in H396P, E279K and T315I, a minimum appears in correspondence of
the fully open A-loop conformation (basin A, Figure 6.11), proving that as observed
for oncogenic mutants[100], more open A-loop conformations are also explored by the
imatinib resistant mutants, even in the non phosphorylated form.
For E450K fully open A-loop conformations are visited with a barrier of 3
kcal/mol, while for H396P completely open conformations (CV1 values lower than
5, see Figure 6.11) are sampled but not fully stable. E279K and T315I seem to present
an opening tendency as well, with a landscape more similar to the one of Src with high
barriers to cross. The T315I mutant, like Abl WT, has a single broad minimum, that
corresponds to the semi-open A-loop conformation (see Figure 6.11). It seems that just
G250E, E450K and H396P are able to overcome the high barriers towards a fully open
A-loop conformation. This could be probably correlated with the unfolding events of
the αG and αC helices, previously described. Indeed, referring to literature, conforma-
tional transitions could be associated with the unfolding of crucial structural elements
("cracking" points[216, 101], see Introduction 1.5.1).
6.7 Binding free-energy of imatinib to Abl and T315I
mutant
Among all the resistant mutants considered in the study, the "gatekeeper" T315I is a
remarkable exception. Not only because it is known to affect directly the binding of
imatinib, but also because it does not alter the free energy of the DFG flip and it shows
just a weak tendency to visit open A-loop conformations. However, it extensively sam-
ples the DFG-in active conformation, as shown in Figure 6.4 by the broad minimum
of the FES. To better understand the mode of action of the T315I mutant and to verify
the recently proposed induced fit theory[80, 79], the (un-)binding free energy profile of
imatinib to both Abl WT and T315I was reconstructed (see Section 2.1.6).
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Figure 6.12 illustrates the important differences between the binding mechanism in
the two kinases. In both cases, the deepest minimum of the FES (basin A) corresponds
to the kinase bound to imatinib, in the conformation seen in the crystal structure. In
Abl WT only one unbinding pathway can be identified, characterised by an additional
metastable minimum which corresponds to an external binding pose, where imatinib
slides below the αC-helix (basin B, Figure 6.12). It is noticeable that when imatinib ap-
proaches the binding site (basin C), the DFG motif is already in the DFG-out conforma-
tion thus, validating the theory of a conformational selection mechanism[20, 78, 187].
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Figure 6.12: Reconstruction of the (un-)binding FES of imatinib to Abl and T315I. The struc-
tures corresponding to the local minima and transition states of the FES are identified with
letters. Shown in green stick is the drug imatinib. In the structures of the T315I, the mutation is
shown in red sticks. The error on the minima and barriers of the FESs amounts to 0.5 kcal/mol.
Figure taken from Ref [93].
On the contrary, in the gatekeeper mutant not only is the barrier to unbinding 2
kcal/mol lower than in the WT, but imatinib has two distinct unbinding pathways (via
6.8. Discussion 140
B’ or via E, Figure 6.12). The first pathway resembles the one of Abl WT (via B’,
Figure 6.12), however the shift from the external pose (basin C’) to the docked one is
hampered by a higher energy barrier with no stable intermediate states (B’). The energy
gain for T315I in the passage from C’ to A’ is lower than for Abl WT (∆G of 6 and 8,
respectively) thus, disfavouring the binding and in agreement with the higher imatinib
IC50 value registered for the mutant. The alternative pathway for the gatekeeper mutant
(via D and E), sees imatinib sliding below the P-loop and binding to the kinase through
the ATP site. This pathway was originally proposed as the main mechanism of binding
of type I inhibitors while, for type II inhibitors both binding pathways were thought to
be feasible[217].
As mentioned previously, an induced fit mechanism has been proposed for Abl
WT, involving the P-loop, and responsible for the high binding affinity towards
imatinib[80, 79]. The simulations instead point towards a two step mechanism of bind-
ing of imatinib to Abl WT: a conformational selection step followed by an induced
fit. When imatinib approaches the binding site (basin C, Figure 6.12), the kinase al-
ready adopts the DFG-out conformation (conformational selection) and subsequently,
the main structural change between basin B and the more stable basin A is effectively
the conformational change of the P-loop, with the adoption of the kinked conforma-
tion (induced fit). In the "gatekeeper" mutant, both mechanisms seem to be affected
by the mutation. On the one hand, the DFG-out conformation is destabilised by the
adoption of the Asp-down intermediate (basin C’, Figure 6.12). On the other hand,
the more variable landscape, close to basin A, is characterised by a broader metastable
minimum, symptom of a general instability of imatinib in the binding site.
6.8 Discussion
The analyses performed in this chapter shed light on the multiple mechanisms of sev-
eral imatinib resistant mutants: the destabilisation of the inactive DFG-out conforma-
tion together with the opening of the A-loop favour the shift towards the kinase active
conformation and lead to a direct ATP competition. Eventually, every mutant would
adopt one or both mechanisms to lower imatinib affinity towards Abl WT.
The RMSF analyses show a significant trend, for which the mutations conferring
resistance generally determine a reduction of the sub-µs dynamics. The equilibrium
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between the DFG-in and DFG-out conformations has been proved to be a delicate bal-
ance between entropic and enthalpic contributions, as seen for the G250E and T315I
mutants. In this perspective, the changes in the sub-µs dynamics could be predictive of
the DFG-out conformation energetics.
As for Src, the study of the mutants of Abl was helpful for the understanding
of the allosteric connections regulating the Abl KD (see Figure 6.13). In agreement
with the allosteric coupling analysis (see Section 4.2), the A-loop and the αC-helix
of Abl result to be strongly correlated, proved by the cross-effect of the E279K and
H296P mutations. The P-loop, whose mutation G250E affects the A-loop dynamics
and the N-lobe loops in general as well takes part in this interplay. The αG-helix, on
the contrary, seems to play a marginal role in Abl, as mutants in it do not rigidify the
A-loop, and have the weakest effect on imatinib IC50.
DFG
αC-helixP-loop
αG-helix
E279K
G250E
H396P
E450K
imatinib
β3-αC loop
T315I
Activation 
loop
Figure 6.13: Structure with highlighted by red dots the location of the resistant mutants of Abl.
Red arrows illustrate the dominant allosteric pathways identified by the analyses performed.
The connection between the αC-helix and the A-loop is a feature of the Abl structure.
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Finally, the (un-)binding free energies of imatinib to Abl WT and to T315I have
unveiled both mechanisms of binding. Indeed, contrary to what was stated in recent
papers[79, 80], imatinib binds to Abl WT first by selecting the DFG-out conformation
and subsequently the binding is stabilised by an induced fit, with the P-loop adopt-
ing the kinked conformation. The loss of both mechanisms in the "gatekeeper" mu-
tant, together with the loss of an hydrogen bond crucial for the stabilisation of the
binding[91, 61], are in agreement with the lower affinity of imatinib for the mutant.
Chapter 7
Conclusions
In this thesis, I have investigated the molecular mechanisms responsible for the ob-
served differences in imatinib activity towards homologous tyrosine kinases and the
reasons leading to drug resistance. By using a combination of computational and ex-
perimental approaches I found a link between sub-µs dynamics and the conformational
dynamics involved in the regulation of tyrosine kinases (TKs) and in the binding of the
drug imatinib.
In particular, the dynamics of specific functional motifs in TKs, such as the P-loop,
αC-helix and the A-loop are involved in the binding process of drugs. Not only because
they are close to the drug binding site, but also because they are directly or indirectly
(allosterically) involved in the conformational changes that lead to the adoption of the
druggable conformations (DFG-in for type I inhibitors, DFG-out for type II, opening
of the A-loop, etc.).
The sub-µs dynamics was found to be correlated to the conformational dynamics
of this group of kinases. Therefore, the former is able to discriminate binders from
non binders among highly homologous TKs. Indeed, the structural plasticity is able to
influence the large scale domain motions, and influences the free energy penalty of the
DFG-out conformation. Among the kinases studied, Abl (the main target of imatinib)
is very flexible, being able to explore a wider range of conformations, mainly due to
the specific rearrangements of the αC-helix, not observed in other TKs and lost in the
drug-resistant mutants of Abl. Moreover, the dynamics of the functionally-relevant
motifs are highly correlated in Abl, and in particular they are all linked to the flexible
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A-loop. All these elements together concur to stabilise the DFG-out conformation, thus
facilitating the binding of imatinib.
The fact that most imatinib resistant mutants of Abl affect flexible regions con-
firms the role of flexibility. The engineered mutants of Src confirm the link between
flexibility and imatinib affinity. However, the change in the binding affinity of imatinib
to the engineered mutants was smaller than expected. This might be partially due to
the fact that none of the mutants are significantly affected by the A-loop flexibility. In-
deed, the observed changes in the sub-µs dynamics in the clinically relevant mutants
and in some of the TKs are likely to be a symptom of a more profound change of
the conformational free energy landscape. Two mechanisms have been identified: the
destabilisation of the inactive DFG-out conformation and the opening of the A-loop,
with a shift towards the kinase active conformation.
The changes in the sub-µs dynamics reflect (and in part determine) the global
changes of the conformational landscape. More flexible TKs favour the DFG flip and
a larger DFG-out population, while rigid TKs favour the DFG-in active conformation.
The phosphorylation of the A-loop reduces the activity of type II drugs (such as ima-
tinib) but not of type I drugs, as mentioned in Section 1.4.2 of the Introduction, because
it induces a shift towards DFG-in (type I target), lowering the population of DFG-out
(type II target). Moreover, the effect of the phosphorylation in lowering imatinib affin-
ity is much more evident in flexible kinases (as Abl and Kit) than in the more rigid ones
(as Src). This could be explained by the fact that flexible kinases populate the DFG-out
conformations rather than the rigid TKs, so that the population shift for the latter will
be minimum and therefore not changing the already low imatinib activity.
The in-out equilibrium is a delicate balance between entropic and enthalpic contri-
butions, easily affected by even slight changes in the dynamics, as proved in the resis-
tant mutants of Abl. Overall, our analysis points to the fact that imatinib would select
for the DFG-out conformation, but its adoption and stability is influenced by a complex
interplay among allostery, sub-µs dynamics and large conformational changes.
Finally, this work has also helped clarifying the mechanism of binding of ima-
tinib to the Abl T315I "gatekeeper” mutant. In the case of Abl, a two-step mechanism
of binding has been outlined. Imatinib will first select for the DFG-out conformation
and, subsequently, the adoption of the kinked conformation of the P-loop will con-
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fer high stability to the binding. This two-step mechanism has been impaired in the
"gatekeeper" mutant T315I, resulting in a destabilisation of the binding.
On the whole, given the links between sub-µs dynamics and the conformational
changes affecting the inhibitors activity, the former sub-µs dynamics might be used to
predict the effect of mutations on drug binding and allow for the rational drug design
of novel TKs inhibitors more resilient to the emergence of resistance.
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